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ABSTRACT
Dementia is affecting millions of people around the world, and the global preva-
lence will continuously rise. Neuropsychiatric symptoms (NPS) in dementia are 
frequent and constitute a key driving force in the disease burden for both patients, 
families, caregivers and society. The clinical presentation includes symptoms 
such as agitation, depression, anxiety, apathy and irritability, which are highly 
frequent in patients with dementia. NPS have a significant negative impact on a 
patient’s ability to perform activities of daily living and also contribute largely 
to the disease-associated health care costs. Current knowledge of the pathophysi-
ological mechanisms causing NPS is lacking, and improved understanding of these 
processes is of great importance in order to improve treatment of NPS.
The main purpose of this thesis was to examine the pathophysiological mechanisms 
underlying NPS by investigating their associations to cerebrospinal fluid (CSF) 
biomarkers reflecting core Alzheimer’s dementia (AD) pathology (phosphorylated-
tau [P-tau], total-Tau [T-tau], β-amyloid 1-42 [Aβ-1-42]), synaptic degeneration 
(neurogranin [Ng], growth-associated protein 43 [GAP-43]) and axonal degen-
eration (neurofilament light protein [NFL]) in patients with dementia. Secondary 
aims included investigation of how treatment with an acetylcholinesterase inhibitor 
(AChEI) (Galantamine) or antipsychotic (Risperidone) impacts both the clinical 
symptoms and CSF biomarker patterns. In the first study, we showed that agitation 
correlated with increased levels of P-tau and T-tau in CSF, but not with Aβ-1-42. 
Thus, suggesting an association between agitation and tau-mediated pathology. 
The second study was an open randomized clinical trial comparing the efficacy 
of Galantamine and Risperidone for the treatment of agitation in patients with 
dementia. Both drugs were effective in reducing levels of agitation. However, 
Risperidone was more efficient at decreasing NPS, although at the cost of lower 
tolerability and increased rate of adverse events. In the third study, we showed that 
treatment with Risperidone, but not Galantamine, was associated with a decrease 
of CSF Aβ-1-42. Indicating a potential association between Risperidone and pro-
gression of amyloid pathology. In the fourth study, we investigated the association 
between NPS and biomarkers for synaptic degeneration (Ng, GAP-43) and axonal 
degeneration (NFL). Levels of Ng, GAP-43 and NFL did not differ between AD 
patients with high vs low levels of NPS. We also found associations between CSF 
markers for synaptic (Ng, GAP-43) and axonal degeneration (NFL) with NPS, 
especially of the psychotic spectrum, in patients with vascular dementia (VaD).  
In conclusion, our results implicate tau-mediated pathology and synaptic dysfunc-
tion as contributing components to the presence of NPS in AD and VaD. In contrast, 
no clear evidence supporting the role of amyloid pathology in NPS was observed. 
Interestingly, treatment with Risperidone affected CSF Aβ-1-42 levels, providing a 
possible pathway for the previously observed association between use of antipsy-
chotics and accelerated rate of cognitively decline seen in patients with dementia. 
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1 INTRODUCTION
Neuropsychiatric symptoms (NPS) in dementia are a prominent and clinically sig-
nificant feature of neurocognitive disorders. NPS includes a wide array of different 
behavioral abnormalities, for example, psychotic behaviors or mood disorders, 
with typical clinical symptoms including depression, anxiety, apathy, agitation or 
hallucinations (1). Although NPS contributes immensely to the dementia disease 
burden, previous research has mostly been focused on cognitive impairment and 
the decline of memory performance associated with dementia.
Currently, our understanding of the mechanisms causing NPS in dementia is 
limited, although some evidence for the neuropathological alterations associated 
with the development of NPS have started to emerge. Treatment of NPS is also 
currently focused solely on symptom management, whereas no disease-modifying 
drugs are available. Current medications display modest efficacy at best, while 
these symptoms continue to cause enormous distress for both patients and car-
egivers (2). There is, therefore, a great need for improved clinical care, as well as 
a necessity for further basic research, in order to amend the existing knowledge 
gap regarding NPS neuropathology.
The purpose of this thesis was to study the underlying pathophysiological mecha-
nisms associated with NPS through the analysis of correlations with cerebrospinal 
fluid (CSF) biomarkers reflecting core Alzheimer’s disease (AD) pathology (Total-
tau [T-tau], phosphorylated-tau [P-tau], β-amyloid 1-42 [Aβ1-42]), synaptic dys-
function (Neurogranin [Ng], Growth-associated protein 43 [GAP-43]) and axonal 
degeneration (Neurofilament light protein [NFL]). Secondly, the scope of this 
thesis was also to investigate the efficacy of drugs currently used against NPS in 
modern health care (acetylcholinesterase inhibitors and antipsychotics), as well as 
examine the potential effects of these medications on the CSF biomarker patterns. 
Our hope is that this thesis will inspire future research to continue reaching for a 
more comprehensive understating of the neurobiological and pathological altera-
tions involved in the evolution of NPS. Consequently, providing a basis for the 
development of new treatment options, thus improving the quality of life for 
patients, families and caregivers for generations to come.
1.1 Dementia
Dementia, or in updated modern nomenclature, major neurocognitive disorder 
(NCD) (3) is a universal umbrella term for a clinical syndrome caused by a group 
of progressive heterogeneous neurodegenerative diseases resulting in deterioration 
of cognitive functions and a presence of various neuropsychiatric symptom (4). 
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Earlier global estimates have shown that in 2010, approximately 35.6 million 
people suffered from dementia. The prevalence is projected to double every two 
decades, thus anticipating approximately 65.7 million affected patients in 2030 (5). 
The most common form of dementia worldwide is AD constituting approximately 
60-80% of the total prevalence (6). The three other major subtypes of dementia 
diseases include; Vascular dementia (VaD), Dementia with Lewy bodies (DLB) 
and Frontotemporal dementia (FTD) with prevalence estimations at approximately 
20-40%, 5-20% and 5-20% respectively, depending on the literature cited (4,6). 
Other less frequent, but still clinically significant, subtypes of dementia include 
prion-diseases, Huntington’s disease, Parkinson’s disease dementia, alcohol-related 
dementia and normal-pressure hydrocephalus (4,7). The single most important 
risk factor for the development of dementia is age and the prevalence amongst 
individuals older than 65 is approximately 5-10 % with some variations depending 
on geographic region (8). Several other factors contribute to the risk of develop-
ing dementia including; cardiovascular morbidity, prior head injuries, psychiatric 
diseases such as depression and genetic factors, most notably, the presence of the 
ε4 allele variant on the Apolipoprotein E (APOE) gene for AD (8–10). 
The most characteristic clinical symptom in the majority of dementia cases is a 
notable decline in memory functions as well as the presence of NPS (4). Other 
cognitive domains commonly affected include, but are not limited to, deficits in 
executive functions, learning, language, motor functions and attention (4,8). It is 
important to note that although all types of dementia result in an overall impair-
ment of cognitive functioning, the clinical phenotype between dementia subtypes 
may display a large variability depending on the underlying etiologies and associ-
ated disease mechanisms (11). Additionally, it is of significance to understand that 
although different dementia disorders are thought of as distinct neuropathological 
entities, they often coexist concurrently rather than acting solitarily (12). Indeed, 
post mortem autopsy studies conducted have confirmed that dementia patients 
often exhibit mixed pathological alterations including, for example, protein depo-
sitions typical for AD as well as vascular morbidity associated with VaD (12,13).
1.1.1 Mild Cognitive Impairment
Mild cognitive impairment (MCI) is a term describing patients with objective 
impairment in at least one cognitive domain but with preserved independent func-
tionality in daily life, thus not fulfilling the criteria for a dementia diagnosis (14). 
MCI is thought of as an early stage in the dementia disease continuum and often 
associated with AD, but can be caused by different underlying pathologies (15).
The prevalence of MCI is roughly 10-20 % in populations older than 65 years of 
age and more frequent in males as compared to females, but females with MCI 
show an accelerated rate of cognitive decline as compared to males (16,17). 
3
Patients with MCI have an increased risk of developing dementia, and the annual 
conversation rate is approximately 5-20 %  per year with 80% of patients pro-
gressing to dementia within six years after the initial MCI diagnosis (16,18). The 
symptomatology of MCI syndrome is highly heterogeneous, generating historical 
difficulties in establishing adequate diagnostic criteria. Current guidelines divide 
MCI into subtypes depending on the presence of memory deficits referred to as 
amnestic-MCI and non-amnestic MCI (19). Additionally, whether one or more 
cognitive domain(s) are impaired is assessed and denoted as single domain MCI 
or multiple domain MCI, thus creating four potential subtypes when combining 
these parameters (19). 
Of interest, not all patients with neurobiological evidence of preclinical AD, i.e. 
CSF biomarker patterns suggesting AD pathology or even manifest MCI, progress 
on the disease continuum and develop AD or other dementias, despite sharing 
similar cerebral pathological alterations (16,20,21). Predicting which patient will 
progress from MCI to manifest dementia on an individual level is currently impos-
sible, and the reasons for the variability in disease evolution amongst patients are 
not fully understood. Albeit, factors such as APOE genotype and cardiovascular 
co-morbidity are considered to be of importance (20,22).
1.1.2 Alzheimer’s disease 
The term Alzheimer’s disease was first introduced in the early 19th century when 
Dr. Alois Alzheimer, a German psychiatrist and neuropathologist, presented a case 
study on a relatively young woman suffering from inexplicable progressive memory 
loss, disorientation and hallucinations which led to eventual death. Subsequent 
post mortem autopsy studies of her brain conducted by Dr. Alzheimer revealed 
cerebral atrophy and protein depositions representing the classical neuropathologi-
cal manifestations of AD (23,24).
There are two main forms of AD; sporadic or familial AD (FAD). Sporadic AD can 
be further subdivided into late-onset AD (LOAD) and early-onset AD (EOAD). 
LOAD is the overwhelmingly most common form of AD, constituting more than 
95% of all cases, with disease onset over the age of 65 and a mean age of onset 
at 80 years of age (25). EOAD manifests before 65 years of age and is associated 
with a more aggressive clinical course, constituting approximately 5% of all AD 
cases (25–28). FAD is a rare inherited form of the disease, representing less than 
1% of all AD cases (25). FAD is most frequently caused by mutations in one of 
three genes; Amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 
2 (PSEN2) inherited in autosomal dominant fashion. Consequently, offspring to 
patients carrying these mutations have a 50% chance of acquiring the disease (29). 
4
From a clinical perspective, the quintessential feature of AD is progressive  memory 
loss in combination with variable decline in other cognitive domains, often  affecting 
learning capabilities, verbal skills, executive functions and visuospatial abilities, 
simultaneously accompanied by the presence of various NPS (30,31). Since AD 
is a chronic progressive disease existing on a continuous temporal spectrum, 
the clinical symptomatology is highly variable and fluctuates depending on the 
current disease stage of the individual patient (30). Long before memory loss or 
other cognitive deficits can be observed, AD-associated pathological changes can 
be identified in the brain through measurement of CSF biomarkers or imagining 
technique’s, a stage called preclinical AD (21). Patients with preclinical AD can 
progress and develop cognitive impairment, most frequently involving subtle 
changes in memory capabilities, that are objectively verifiable through clinical 
testing using screening instruments such as the Montreal Cognitive Assessment 
(MoCA) or Mini Mental State Examination (MMSE) (32–34). If this progression 
occurs, an MCI diagnosis can be established, the next stage on the AD disease 
continuum (14,21). Although patients with MCI display manifest cognitive impair-
ment, it has per definition of the diagnostic criteria, minor to no impact on their 
ability to adequately perform activities of daily living (ADL) (14).
Some patients with MCI will experience progression of their symptoms causing 
a significant negative impact on their ability to independently conduct activi-
ties of daily life, thus fulfilling the clinical criteria for a diagnosis of dementia 
or major NCD according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) (35). Additionally, further diagnostic procedures include 
assessment of clinical profiles, blood samples to exclude other diseases, 
brain imaging as well as analysis of CSF biomarkers in order to generate evi-
dence to support the final diagnosis of AD or other dementia subtypes (36). 
When a diagnosis has been established the clinical projection of AD can broadly 
be divided into a spectrum consisting of three main stages based on the develop-
ment and presentation of symptoms namely; mild, moderate and severe AD (37). 
The variability in symptoms and disease burden between these stages is of great 
significance, as is the intrapersonal perception of the disease. Mild AD has lower, 
yet significant, impact on cognitive capabilities and the ability to live a normal life 
whereas patients who progressed to severe AD display both a major deterioration 
of general cognitive capabilities and debilitating NPS (30). At this stage of the 
disease patients are unable to perform almost any ADL functions, consequently 
leading to institutionalization or constant care and supervision provided by their 
family members (30,38–40). 
Due to the earlier research of Dr. Alzheimer and others, we can today with high 
accuracy describe the core neuropathological hallmarks of AD. Typical features 
include cerebral protein deposition causing amyloid plaques (AP) and  neurofibrillary 
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tangles (NFT) with associated synaptic loss and dysfunction, ultimately result-
ing in neuronal death, gliosis and brain atrophy, most commonly starting in the 
frontal and temporal lobes and progressively extending to other parts of the neo-
cortex (23,25,41). Although these core pathological alterations have been known 
for a relatively long time, their specific contribution and temporal relation to the 
pathogenesis of AD is to this date not completely understood (42). The majority 
of the scientific community tend to agree with the “amyloid cascade hypothesis”, 
suggesting that amyloid pathology is the driving component in AD development 
and that NFT constitute a downstream process, but this linear model of disease 
causality is still debated (25,42,43).
1.1.3 Alzheimer´s pathology – Amyloid plaques
The first pathological hallmark of AD are protein depositions consisting of 
aggregated β-amyloid (Aβ) located to the extracellular space and walls of blood 
vessels in the brain denoted amyloid plaques (25,44). The formation of amyloid 
plaques starts in the frontal and temporal lobe, eventually spreading to the rest of 
the cerebral cortex as the disease progresses (25,44). Amyloid β (Aβ) denotes a 
group of peptides with different isoforms ranging between 37 to 43 amino acids in 
length and exists in two main forms, Aβ1-42 and Aβ1-40, constituted of 42 and 40 
residues respectively (45). The Aβ peptide is formed by cleavage of its precursor, 
amyloid precursor protein (APP), a transmembrane protein genetically located on 
chromosome 21 thought to be involved in several key biological functions includ-
ing survival, repair and growth of neurons (44–46). 
The metabolism of APP involves cleavage by the different proteases denoted α‐, 
β‐ and γ‐secretases (47). The α-secretases include several enzymes belonging to a 
class of proteins called a disintegrin and metalloproteinase (ADAM), β-secretases 
include beta-site APP cleaving enzyme 1 (BACE1) whereas the γ‐secretase is a 
multiprotein complex generated by four different subunits including presenilin 1 
or 2, presenilin enhancer 2, nicastrin and anterior pharynx defective 1 (48). The 
first step involves cleavage of APP by α‐or β‐secretase into one of two pathways; 
the amyloidogenic or nonamyloidogenic (45) (Figure 1). In the nonamyloido-
genic pathway APP is processed by α-secretases, resulting in soluble APPα and 
an 83 amino acid long C-terminal part (C83) which is then further processed by 
γ secretase generating the P3 peptide and APP intracellular domain (AICD) (45).
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Figure 1. Amyloidogenic and nonamyloid pathways of Aβ metabolism
In the amyloidogenic pathway, modulation of APP by β-secretase (BACE1) gen-
erates soluble APPβ and a 99 amino acid long fragment termed (C99) (48). This 
fragment is then further cleaved by γ secretase to several different isoforms of Aβ 
resulting in the formation of two main Aβ isoforms, namely Aβ1-40 and Aβ1-42, 
constituting approximately 60% and 15% of all Aβ peptides when measured in CSF 
(45,47,49). Currently, the normal physiological function of Aβ peptides remain 
elusive, but Aβ has been proposed to be involved in the modulation of synaptic 
activity, plasticity, neuronal survival and memory (50,51). The two main isoforms 
of Aβ display some differences in functional properties. Most importantly, the 42 
amino acid long version is more prone to form oligomers and fibrils, a prerequisite 
for the generation of amyloid plaques (49). Although Aβ1-40 is the most prevalent 
Aβ peptide under normal conditions, Aβ1-42 constitutes the main building block 
of amyloid depositions during AD pathogenesis (49). After Aβ monomers are 
produced intracellularly, they form oligomers that enter the extracellular space, 
a step that is currently poorly understood, where they can further organize into 
protofibrils, which intertwine and develop into mature fibrils in a β-sheet rich 
configuration, the foundation of amyloid plaques (25,44,45). 
Soluble oligomers of Aβ42, more so than mature amyloid plaques, are thought to be 
responsible for the neurotoxic effects on neurons and synapses, triggering several 
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pathological events eventually leading to neuronal death and the development of 
AD (25,52). In early stages of AD, Aβ toxicity seems to have an affinity for cho-
linergic and noradrenergic neurons located in the nucleus basalis of Meynert and 
locus coeruleus (LC) respectively, but serotonergic, dopaminergic and glutamater-
gic neurotransmission is also affected as the disease progresses (53–58). The toxic 
effects of Aβ pathology are mediated through multiple different mechanisms, and 
the Aβ oligomers are thought to be the most toxic species in the Aβ family. They 
can induce oxidative stress by creating free radicals, such as reactive oxidative spe-
cies (ROS), which directly initiate apoptosis through interaction with cell surface 
receptors and activate microglia and astrocyte’s that induce both direct phagocytosis 
of neurons and an inflammatory cascade causing damage to neurons (59,60). Aβ 
can also affect the mitochondria by increased formation of ROS resulting in frag-
mentation of the organelle, while APP aggregates at the mitochondrial membrane 
and alters the electron transport chain resulting in mitochondrial dysfunction and 
increased Aβ production (59). The amyloid plaques cause direct toxicity in their 
immediate proximity by affecting neurites and causing synaptic dysfunction, but 
their role as a regional reserve pool of soluble Aβ oligomers is probably more 
important than their direct neurotoxic effect (61). Furthermore, there is evidence 
suggesting that Aβ oligomers and monomers, through inflammatory processes or 
modulation of cellular kinase/phosphatase activity, generate hyperphosphorylation 
of tau and the formation of neurofibrillary tangles (62). Thus proposing a pathway 
for β-amyloid as the driving factor of AD-associated neurodegeneration which is 
the basis for amyloid cascade hypothesis (25,45,59,60)  
The catabolism and clearance of Aβ from the brain have been extensively stud-
ied since the concentration of cerebral Aβ depends on the equilibrium between 
formation and degradation of Aβ and impaired clearance could hypothetically be 
the genesis of AD (48). In fact, there is growing evidence that deceased degrada-
tion and clearance of Aβ is the major contributor to late-onset AD whereas the 
production rates of Aβ are more or less unaffected in this patient group (63,64).
There are three fundamental ways of clearing Aβ peptides from the brain; trans-
port of Aβ over the blood brain barrier (BBB), extracellular proteolytic degra-
dation or receptor-mediated endocytosis by glial cells or macrophages (10,65). 
Clearance via transportation of Aβ peptides from the central nervous system (CNS) 
is accomplished through two main processes; either directly into the systemic blood 
circulation via passage through transport proteins over the BBB or drainage into 
CSF from where it continues into the blood circulation or lymphatic system (66). 
Efflux of Aβ peptides directly over the BBB is the primary way of clearance via 
transportation and is mediated by several membrane receptors, but two are of par-
ticular importance, the low-density lipoprotein receptor-related protein 1 (LRP1) 
and ATP dependent P-glycoprotein 1, whereas the influx of Aβ is regulated by 
8
receptor for advanced glycation end products (RAGE) (41). In AD, the expression 
of both LRP1 and P-glycoprotein receptors are downregulated, whereas expres-
sion of the influx transporter RAGE is increased (66). Simultaneously, oxidative 
stress caused by the disease process decreases the affinity of Aβ binding proteins 
in the blood circulation, thus permitting more influx of Aβ through RAGE (66). 
Proteolytic degradation of Aβ peptides is an extracellular process in which pre-
dominantly different glial cells, such as astrocytes or microglia, produce and secrete 
different proteases which can cleave Aβ at various sites of the peptide (65,67). 
The most important enzymes involved in this process include; neprilysin (NEP), 
insulin-degrading enzyme (IDE), matrix metalloproteinases (MMPs), endothelin-
converting enzyme (ECE), plasmin and angiotensin-converting enzyme (ACE) (67). 
The exact role and importance of the mediators of proteolytic degradation are yet to 
be determined, but NEP and IDE seem to play a crucial role in Aβ homeostasis (48). 
Transgenic mice with increased levels of these enzymes show reduced Aβ burden 
and no formation of amyloid plaques (68), while the decreased activity of both NEP 
and IDE has been shown in AD patients as compared to healthy controls (69,70) 
The third way of Aβ clearance involves internalization and degradation of Aβ 
compounds into the intracellular environment of astrocytes, microglia and mac-
rophages. This predominantly occurs through receptor-mediated endocytosis of 
fibrillary and oligomeric Aβ, but phagocytosis and pinocytosis also occur, albeit 
at a lower rate (65). Several different receptors are involved in endocytosis of Aβ 
peptides, including the LRP1 and RAGE but also scavenger receptors and toll-
like receptors (65). Once endocytosis is completed the cell proceeds to degrade 
the internalized proteins using the ubiquitin-proteasome system or lysosomal 
processing, both of which can be pathologically altered during AD reducing the 
clearance capabilities of Aβ (66,67).
Our understating of Aβ metabolism, its relation to amyloid plaques, as well as the 
identification of mutations associated with familial AD that result in the cerebral 
accumulation of Aβ (APP, PSEN1 and PSEN2) constitutes the basis for the pos-
tulation of the amyloid cascade hypothesis (71). The hypothesis suggests that Aβ 
driven pathology is the upstream event to all neuropathological changes found in 
AD. The majority of all FAD patients have mutations in one of these three genes, 
resulting in an overproduction of Aβ1-42 and increased ratios between Aβ1-42 
and Aβ1-40 (25,29,72). Furthermore, studies of different transgenic mice models 
with mutations in FAD associated genes develop clinical and neuropathological 
features typical of AD, including amyloid plaques, synaptic loss, dystrophic neurites 
and gliosis (73). Patients with Downs syndrome, who are born with three copies 
of chromosome 21 containing the APP gene, display neuropathological changes 
close to those in AD 30 years earlier than healthy controls (74,75). 
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1.1.4 Alzheimer’s pathology – Neurofibrillary Tangles 
The second classical hallmark of AD neuropathology is the intracellular formation of 
neurofibrillary tangles in axons, dendrites and soma of neurons (76). The main compo-
nent of NFTs is tau, a microtubule-associated protein (MAP) found almost exclusively 
in neurons and genetically coded on the MAPT gene located on chromosome 17 (77). 
Tau exists in 6 different isoforms, ranging in length between 352 to 441 amino 
acids, with a tubulin-binding domain at the C-terminal and a projection domain at 
the N-terminal which interacts with cellular proteins, membranes and organelles 
such as mitochondria (77). The isoforms differ in the C-terminal by having either 
3 or 4 microtubule binding region (MTBR) repeats, referred to as R3 or R4, and 
in the N-terminal by having up to two additional amino acid sequence inserts (77). 
Although they have principally the same functionality, they likely display specific 
physiological roles, supported by the fact that expression of the different isoforms 
is variable depending on the developmental stage (77,78).
The elementary function of tau is to act a stabilizer of microtubules in neuronal 
axons (78). Tau binding stimulates polymerization of microtubules, and the pro-
tein is also a critical component of the axonal transport machinery (77–79). The 
projection domain of tau regulates the distance between microtubules in axons. 
It binds to proteins, including spectrin and actin filaments, which enables a con-
nection with neurofilaments and microfilaments, thus playing a pivotal role in 
the regulation of the cellular cytoskeleton and neuronal morphology (77–79). 
Under physiological conditions, the modulation of tau binding to microtubules 
is achieved through several different posttranslational modifications. The most 
important mechanism involves phosphorylation or dephosphorylation of tau, at 
one of the approximately 80 serine and threonine residues by intracellular kinases 
and phosphatases (78,80). This is a dynamic process under careful equilibrium, 
constantly causing tau to bind and release from microtubules, depending on the 
phosphorylation state of tau, where increased phosphorylation results in decreased 
binding affinity (78–80).
Under pathological conditions, such as during AD development, tau disengages 
from the microtubules resulting in translocation of tau from the axon to the soma-
todendritic compartment, causing higher concentrations of unbound tau in the 
cytosol (78,81). Consequently, the monomeric tau protein undergoes dimeriza-
tion forming tau-dimers which then start to self-assemble into oligomers, which 
can further elongate and aggregate to generate paired-helical filaments (PHF) 
and straight filaments, the building blocks of neurofibrillary tangles seen in AD 
(80,82,83) (Figure 2). 
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Figure 2. Tau-associated AD pathology
Several hypotheses have been proposed for the pathological alterations required 
in creating the adequate conditions for the abnormal disengagement of tau 
from microtubules, and subsequent misfolding and self-aggregation into NFTs. 
It seems evident that several post-translational mechanisms, including hyper-
phosphorylation, truncation, acetylation, nitration, glycosylation, ubiquitination 
and glycation are needed to change the conformational state of tau. These pro-
tein alterations promote detachment of tau from microtubules and polymeriza-
tion into dimers, oligomers, PHFs and finally neurofibrillary tangles (80,82,84). 
Of these different post-translational mechanisms, hyperphosphorylation of tau seems 
to be of most importance to engineer the right conditions for tau pathology. Although, 
but the exact significance and temporal distribution of these factors remain to be 
established (80). Under physiological conditions, tau is a highly soluble protein and 
does not aggregate spontaneously as Aβ1-42 (85). The MTBR repeats in tau display 
β-structure and are prone to self-assembly, but this is usually inhibited by the intact N- 
and C-terminals which block these regions from interacting and aggregating (79,83). 
Post-translational hyperphosphorylation of tau is thought to be one of the earliest 
and most essential steps in the pathology associated with AD, caused by dysregu-
lation of the balance between kinases and phosphatases (84). Several kinases are 
upregulated in AD, including Glycogen synthase kinase 3β and Cyclin-dependent 
protein kinase-5, whereas the activity of protein phosphatase 2A is reduced (80,84). 
In total, the phosphorylation state of tau is approximately four times higher in AD 
patients as compared to healthy subjects (80,84). This has several effects on tau, 
including a decreased affinity for binding to microtubules, stimulates the reloca-
tion of tau to the somatodendritic compartments and generates conformational 
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changes exposing the MTBR regions, prone to aggregation consequently promot-
ing polymerization (79,84). Of interest, AICD transgenic mice show an increased 
level of tau phosphorylation and neurodegeneration independent of Aβ, suggesting 
a possible link between tau and Aβ pathology (86).
A second important step in the formation of NFTs is the truncation, or pro-
teolytic cleavage of tau, into smaller parts more prone to aggregation. Several 
cleavage sites have been identified, but activation of Caspase 3 and sub-
sequent truncation at aspartic acid residue 421, has been shown to promote 
protein aggregation in vitro (87). Overall, truncation seems to be a crucial 
step in the promotion of tau-pathology, with these smaller fragments dis-
playing increased aggregation into PHFs and eventually mature tangles (82). 
Through a complex series of modifications including phosphorylation, truncations 
and other post-translational mechanisms the tau-protein obtains the properties 
necessary for agglomeration into higher-order structures such as PHFs, straight 
filaments and eventually intracellular neurofibrillary tangles. 
There are two principal pathways in which tau-mediated neurodegeneration is thought 
to occur. Firstly, the loss of normal physiological function of tau results in a wide 
array of pathological events in neurons (88). The detachment of tau from microtu-
bules causes disturbances in the structural and regulatory role of the cytoskeleton 
and impaired axonal transport, eventually resulting in neuronal dysfunction and cell 
death (79,84,88). Additionally, translocation of tau from axons and misallocation 
in dendritic spines results in synaptic dysfunction (89). The second way includes 
direct toxicity from NFTs and its intermediates. NFTs were long thought to be the 
primary toxic form of AD-associated neurodegeneration, due to the fact that cognitive 
impairment is better correlated with the amount of NFTs as compared to amyloid 
plaques (90). Mature tangles and large fibrils may contribute to neurodegenera-
tion via molecular crowding and neurons with NFTs display fewer synapses (84). 
However, recent research has shown that the presence of NFTs is not mandatory 
for neuronal dysfunction, nor does it inhibit local neuronal circuits (91). Instead, 
small soluble intermediates, such as the oligomers, constitute the primary form of 
toxic tau species causing neuronal loss and synaptic dysfunction (92,93). Levels 
of tau oligomers are correlated with clinical symptoms in AD and are tentatively 
suspected of inducing neurodegeneration via mitochondrial dysfunction while 
spreading between neurons using prion-like mechanisms (92).
The spatial and temporal distribution of NFTs in AD has long been established to 
start in the entorhinal cortex, later progressing to the hippocampus and eventually 
large parts of the neocortex, classically described by Braak staging (I-VI) (81,94) 
(Figure 3). Recently, the presence of hyperphosphorylated tau in noradrenergic 
neurons in LC has been suggested as the first pathological change observed in AD 
(95). These changes are often evident when patients are in their mid-twenties, thus 
implicating tau as the driving component in AD pathology (95).
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1.1.5 Alzheimer’s genetics – APOE
Genetics is an important risk factor for developing AD (96). Previous studies on 
twins have indicated that hereditability is a significant contributor to sporadic AD, 
with more than 60 % of the variation in clinical phenotype attributed to genetic 
factors (97). FAD is known to be caused by various mutations in specific genes 
coding for the APP, presenilin-1 and presenilin-2 proteins, explaining approxi-
mately 50% of all cases (96). Thus, also implying the existence of other relevant 
genetic mutations contributing to FAD, which we are currently not aware of (96).
Unlike FAD, sporadic AD is not caused by deterministic inherited mutations, but 
rather by a combination of environmental factors and multiple genetic risk factors, 
so-called susceptibility genes (29). The most known and studied susceptibility 
gene to this date is the one coding for the ε4 allele of Apolipoprotein E (APOE). 
Apolipoprotein E (APOE) is a 299 amino acid long protein involved in lipid 
homeostasis with its genetic information stored on chromosome 19 (98). Three 
polymorphic alleles on the APOE gene, denoted ε2 (APOE-ε2), ε3 (APOE-ε3) and 
ε4 (APOE-ε4), encode the three most common isoforms of the protein (APOE2, 
APOE3, APOE4), with a global prevalence of 8.4%, 77.9% and 13.7% respectively 
(10). The isoforms diverge at most by two amino acids at position 112 and 158, 
generating APOE2 (Cys112, Cys158), APOE3 (Cys112, Arg158), and APOE4 
(Arg112, Arg158), but this small variation in the amino acid sequence has profound 
effects on the lifetime risk of developing AD (99). 
APOE genotype polymorphism is the single most significant genetic risk factor known in 
the development of sporadic AD. Carriers on the ε4 allele present an increased probability 
of disease development, whereas the presence of the ε2 allele is a protective factor (100). 
The ε4 allele is greatly overrepresented in AD, with approximately 40% of patients show-
ing this genetic variation, as compared to roughly 14 % in the general population (10). 
Heterozygous carriers of the ε4 allele have a threefold increase in the risk of acquir-
ing AD, while homozygous carriers display a staggering 12-fold increase in the risk 
of disease development, as compared to non-carriers (25). Additionally, carriers of 
APOE-ε4 develop AD at a younger age, with heterozygotes being diagnosed on 
average 2-5 years earlier, and homozygotes 5-10 years earlier as compared to non-
carriers (99). In contrast, carriers of the ε2 allele show decreased risk of developing 
AD, and if diagnosed display milder cerebral pathology as well as less cognitive 
impairment (99,101). In total, APOE genotype is thought to explain up to 50 % of 
all late-onset AD cases (102).
APOE is in the CNS mainly produced by astrocytes and functionally contains 
two domains, the N-terminal receptor-binding domain and the C-terminal lipid-
binding domain. It functions as a transporting protein, involved in the transfer of 
lipids between neurons and over the cellular membrane (98). APOE attaches to 
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high-density lipoproteins in the CNS and promotes receptor-mediated endocytosis 
of cholesterol by binding to cell-surface APOE receptors, belonging to the low-
density lipoprotein receptor (LDLR) family which includes the LRP1-receptor 
(10,99). The small changes in amino acid sequence between the three isoforms 
produce large physiological effects by changing the structure, stability and affin-
ity for binding to APOE receptors as well as different lipids (25,98). APOE2 dis-
plays 50-100 times lower binding affinity for the LDRL as compared to APOE3 
or APOE4, while APOE4 has been shown to be less stable than APOE3 (98,99). 
Several hypotheses have been postulated for how APOE affects the path-
ological processes associated with AD, mostly focusing on amyloid 
driven pathology, but Aβ independent pathways have also been proposed. 
Several studies, both human and animal, have shown that APOE genotype is asso-
ciated with levels of Aβ and amyloid plaques in an isoform dependent manner, 
with ε4 carriers displaying the highest Aβ concentrations (10,25,103). In the CNS, 
APOE can bind soluble Aβ and promote cellular uptake via receptors, such as the 
LRP1, at an isoform dependent rate, with APOE4 showing the lowest affinity for 
Aβ (10). Furthermore, APOE genotype has been suggested to affect the clearance 
rate of Aβ over the BBB and effectiveness of intracellular proteolytic degradation 
of Aβ (10). The exact role of APOE in AD pathology is not currently established. 
However, the lipoprotein is thought to contribute by acting as a chaperon protein 
for Aβ, affecting the clearance rate and the amount of Aβ depositions (25). Some 
Aβ independent pathways mechanisms for APOE in AD pathology have been 
proposed. These include potential genotype-dependent hyperphosphorylation of 
tau, regulation of neuroinflammation and mitochondrial dysfunction, but the exact 
role of APOE in these mechanisms remain to be established (98,99).
Figure 3. Spatial distribution of APs and NFTs during AD progression
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1.1.6 Vascular dementia
Vascular dementia (VaD) is the second most common subtype of dementia, consti-
tuting approximately 20% of all dementia cases, and cerebrovascular morbidity is 
a major risk factor for developing dementia (6,104,105). About 20% of all patients 
surviving a stroke will develop dementia in their lifetime (106). In modern literature, 
the term vascular cognitive impairment (VCI), has been introduced to describe 
the full spectrum of clinical phenotypes from vascular-MCI to VaD (104,105). 
The term VCI encompasses a heterogeneous group of vascular disorders, with 
distinct cerebrovascular pathology, contributing to the development of dementia or 
cognitive impairment, and are broadly defined as a loss of cognitive function due 
to ischemic or hemorrhagic infarctions and subsequent brain dysfunction (107).
The vascular abnormalities in VCI can broadly be divided into the disease of large 
or small cerebral vessels, and VaD can further be subdivided into three main sub-
types based on the predominant underlying vascular neuropathology; Multi-infarct 
dementia (cortical vascular dementia), small vessel dementia (subcortical vascular 
dementia) and strategic infarct dementia. (104,108). The vascular changes causing 
these subtypes are heterogeneous and different types of vascular abnormalities 
often coexist simultaneously (104).
The most prevalent subtype of VCI is multi-infarct dementia, caused by cerebro-
vascular disease of predominantly large vessels with arteriosclerosis and subsequent 
thromboembolic events. These events cause multiple cortical infarcts of various size 
and often affect the cingulate and temporal neocortex (105,109). Strategic infarct 
dementia is also associated with large vessel pathology, but in contrast to multi-infarct 
dementia only affects specific brain regions involved in cognition such as thalamus or 
hippocampus due to single infarcts (105). Small vessel dementia is characterized by 
lacunar infarcts affecting subcortical brain regions as well as cortical and subcortical 
microinfarcts (110). These pathological changes arise due to underlying hypertension 
and arteriosclerosis, resulting in diffuse white matter lesions showing demyelination, 
axonal loss and gliosis, which eventually results in cognitive impairment (110).
From a clinical perspective, VCI/VaD is characterized by three key concepts; cog-
nitive decline, confirmation of vascular pathology by imaging modalities, and in 
the case of strategic or multi-infarct dementia presence of a temporal relationship 
between onset of cognitive impairment and vascular disease (111). In contrast to 
AD, the clinical presentation of VaD is more diverse, and memory is not always 
the cognitive domain presenting the most severe deterioration (104). The broad 
spectrum of clinical manifestations in VCI is caused by the spatial specificity of 
the underlying pathology. Since cerebral damage is often more focal then global, 
the affected brain region will determine the clinical presentation, and because sub-
cortical regions are often involved patients display more impairments in executive 
function, attention and information processing (104).
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1.1.7 Frontotemporal dementia
Frontotemporal dementia (FTD) is used as an umbrella term describing a het-
erogeneous group of clinical syndromes, with divergent symptomatology and 
underlying pathophysiology. These syndromes are united by the presence of focal 
neurodegeneration located to the prefrontal and anterior temporal neocortex (112). 
Clinically, it is predominantly characterized by deterioration of executive function-
ing, behavioral changes and language impairment, often affecting patients under 
the age of 65 (113). FTD is divided into two main categories depending on clinical 
presentation; behavioral variant FTD and language variant FTD (114). Behavioral 
FTD accounts for approximately 50% of all cases and features symptoms such 
as progressive personality changes, deterioration in social functioning, apathy or 
disinhibition, which are often misdiagnosed as a psychiatric illness at early stages 
of the disease (115). The language variant of FTD, also known as primary pro-
gressive aphasia, can further be subdivided into non-fluent or semantic variants 
(113). The non-fluent version present with impairment in speech production or 
grammar, whereas the semantic variant displays decreased semantic knowledge 
and word comprehension (113,116)  
The pathology of FTD is extremely heterogeneous and complex. Roughly 10% 
of the disease cases are deterministically hereditary, in an autosomal dominant 
manner, often caused by mutations in the MAPT gene (113). The predominant 
neuropathological features of frontotemporal lobar degeneration (FTLD) include 
gliosis, neuronal loss and microvacuolation in the frontal and temporal lobes that 
are caused by different protein depositions in the brain (112). Three main histo-
logical subgroups can be found classified depending on which protein is accu-
mulated in the brain: FTLD-tau, FTLD-TDP and FTLD-FUS (117). FTLD-tau 
constitutes approximately 40% of all cases and is caused by the accumulation of 
tau protein. The typical pathological finding in FTLD-tau is the presence of bal-
looned neurons, referred to as Pick’s cell (115). In the rest of FTD patient’s tau 
pathology is nonexistent. Instead, approximately 50% of cases are caused by the 
accumulation of TAR DNA-binding protein 43 (FTLD-TDP), and the majority 
of the remaining cases are associated with aggregation of the fused in sarcoma 
protein (FTLD-FUS) (113).
1.1.8 Lewy body diseases
Lewy body disease (LBD) is an umbrella term for diseases caused by α-synuclein 
pathology, including both Parkinson’s disease dementia (PDD) and dementia 
with Lewy bodies (DLB) (118). Although Parkinson’s disease is primarily con-
sidered a motor disorder, the presence of dementia is common, with patients 
showing a risk of developing dementia up to six times as high when compared 
to healthy elderly individuals (119). The pathological hallmark of LBD is the 
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presence of intraneuronal protein depositions composed of α-synuclein, referred 
to as Lewy bodies (LB), often localized to structures in the cortex, brainstem 
and limbic area. LBD results in the loss of predominantly dopaminergic neu-
rons, but also affect cholinergic and noradrenergic neurotransmission (118,120). 
Similar to tau pathology, the smaller intermediates of Lewy bodies such as 
α-synuclein oligomers or fibrils, are thought to be the main neurotoxic compo-
nent in the disease process (118). In contrast, mature LBs have been suggested to 
have a neuroprotective effect (118,120). The oligomers or fibrils of α-synuclein 
are thought to alter cell membrane permeability, cause histone dysfunction and 
inhibit the function of neuronal survival factors, thus resulting in  neurodegen-
eration (120). The spatial distribution of LB constitutes an important difference 
between PDD and DLB. In DLB, the protein inclusions are diffusely located to 
large areas of the cerebral cortex. In contrast, LBs in PDD display a more specific 
pattern affecting predominantly dopaminergic neurons in the substantia nigra, thus 
resulting in the parkinsonian symptoms seen in PDD (121). DLB also frequently 
coexist with simultaneous AD pathology, and patients diagnosed with AD are often 
found to have LB associated pathology at autopsy (122).
The core clinical features of DLB include fluctuating cognitive impairment, visual 
hallucinations, and physical symptoms relating to parkinsonism (122). The typi-
cal fluctuations in cognitive performance are characteristic of DLB and present 
clinical similarities to delirium (122). Presence of visual hallucinations is also 
characteristic and experienced in approximately 80% of all cases, which may help 
to discriminate DLB from other dementias (122). The clinical profile of PDD is 
similar to DLB, but with less visual hallucinations and more motor symptoms, 
and patients typically present with less memory dysfunction as compared to AD 
(118,123). One key clinical difference is the temporal association between the 
onset of dementia and motor symptoms. In PDD, parkinsonism develops at least 
one year before the debut of cognitive symptoms, whereas motor symptoms com-
monly start after cognitive impairment in DLB. (122,124). 
1.1.9 Mixed dementia
Different dementia disorders are conceptually thought of as distinct entities with 
specific and exclusive neuropathology, existing independently of each other. 
However, several postmortem autopsy studies on dementia patients have shown that 
various pathological changes often overlap and exist simultaneously (12,13,125). 
For example, pathology consistent with AD often coexist with cerebral vascular 
disease associated with VaD, then referred to as mixed type dementia (MIX) (126).
The prevalence numbers for MIX are quite diverging between  different stud-
ies indicating that between 10-74% of patients display MIX type  pathology, 
and the largest study to this date indicates that MIX is present in more 
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than 50% of all dementia patients (12). Recently, a review of prior stud-
ies focused on the co-occurrence of AD and VaD found that 22% of patients 
displayed pathological findings associated with both diseases (127). 
Although the frequent existence of multiple types of neuropathological changes in 
dementia patients is evident, the specific contribution and interaction between these 
disease processes remain to be discovered (126,128). Of interest, previous studies 
have shown that multiple pathologies increases the risk of developing dementia, 
and is associated with the severity of the disease, suggesting potential synergistic 
effects between the underlying disease mechanisms (12,129).
1.2 Neuropsychiatric symptoms in dementia
Although memory loss is the primary feature associated with AD in the eye of the 
general public, many different behavioral and psychiatric disturbances are central 
features of AD and other dementia diseases (130). These non-cognitive symptoms 
include, for example, depression, apathy, agitation, disinhibition or psychosis and 
are in modern literature most commonly referred to as neuropsychiatric symptoms 
(NPS) in dementia. Albeit, the term behavioral and psychological symptoms in 
dementia (BPSD) can be used interchangeably (131).
NPS encompasses a wide array of heterogeneous symptoms, ranging from anxiety 
to delusions, and previous research has tried to factor NPS into larger clusters of 
clinically related symptoms. Albeit this research is somewhat inconsistent, many 
studies have described three main clusters consisting of behavioral dysfunction, 
mood disorders and psychosis. However, other classifications have been pro-
posed, and the terminology used to describe these clusters differ between studies 
(1,131,132). The behavioral cluster includes symptoms such as agitation/aggres-
sion, aberrant motor behavior, disinhibition and irritability. Mood disturbances 
incorporate, for example, depression, apathy or anxiety, while the psychosis cluster 
primarily describe delusions and hallucinations (1) (Figure 4).
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Figure 4. Clusters of NPS
NPS are a key clinical feature of dementia and constitute a major part of the disease 
burden. Presence of NPS has a profound effect on both patients and caregivers, 
diminishes the ability to perform ADL functions, while also being associate with 
increased hospitalization rates as well accelerated disease progression and mor-
tality (133–140). Furthermore, NPS constitute the most important determinant of 
caregiver burden, contributes to an enormous need for informal caregiving and has 
a significant impact on health care costs, with studies indicating that up to 30% of 
all dementia associated costs are attributed to NPS (141–147). 
1.2.1 Epidemiology of NPS
NPS in dementia are incredibly prevalent, and most patients are, to some degree, 
affected by non-cognitive symptoms. Data from two large American studies 
show that 75% of dementia patients are affected by at least one neuropsychiatric 
symptom, and 55 % experience two or more symptoms simultaneously, while the 
five-year prevalence of any NPS is 97 % (148,149). Similarly, studies conducted 
in Scandinavia and other parts of Europe, including dementia patients living in 
nursing homes, display prevalence’s rates for clinically significant NPS at 72% 
and upwards (150–152). These studies include patient groups with different types 
of dementia subtypes, generating a reasonable estimate of the real-life presence of 
NPS. Although prevalence numbers for specific psychiatric symptoms are somewhat 
19
fluctuating between studies, they indicate that the most common manifestations 
of NPS in general include depression, apathy and anxiety, with a five-year point 
prevalence of 77 %, 71 % and 62 % respectively (148).
In general, the majority of neuropsychiatric symptoms except for depression, seem 
to increase in frequency consistently over time, and their prevalence is associated 
with both dementia severity at baseline and disease progression (153,154). Presence 
of NPS has also been shown to differ depending on gender. Males show overall 
higher frequencies of psychiatric symptoms, especially increased levels of delu-
sions, agitation, apathy, disinhibition, irritability and nighttime disturbances. In 
contrast, females tend to display higher levels of depression, whereas age is not 
independently associated with NPS burden (154). 
1.2.2 NPS in dementia subtypes and MCI 
While NPS are very frequent and affect all types of dementia, there are some 
differences in prevalence and trajectories of psychiatric symptoms depending 
on the diagnostic subgroup  (154). Overall, patients with AD pathology seem to 
have lower levels of NPS as compared to other types of dementia, with apathy 
being the most common manifestation (154,155). A recent meta-analysis of NPS 
prevalence in patients with AD indicated that apathy, depression, aggression and 
anxiety are the most common behavioral disturbances, with an overall prevalence 
of 49%, 42%, 40% and 39% respectively (156). Previous research has also shown 
that disease duration, level of education and severity of cognitive symptoms are 
associated with increased NPS burden in patients with AD (156), and all NPS 
except euphoria seem to increase as cognitive function decreases (157). 
Overall, AD and VaD display a relatively similar clinical profile  regarding the 
presentation of NPS (158). Vascular type pathology is associated with more 
agitation and sleep disturbances as compared to AD, with depression, apa-
thy, sleep disturbances and anxiety increasing most in severity as cogni-
tive function declines in the setting of VaD (157,159–161). Hallucinations 
and delusions are more common in AD as compared to VaD (162). 
A diagnosis of FTD is associated with increased overall levels of NPS compared 
to other dementia subtypes, and symptoms such as apathy, agitation, anxiety and 
disinhibition seem to be especially common. Additionally, psychotic symptoms 
are also frequent, supporting a previously stipulated hypothesis that schizophre-
nia and FTD may share underlying pathological pathways (154,157,163,164). 
As expected, patients with DLB experience more visual hallucinations as compared 
to other dementia subtypes since it is a core feature of the clinical profile, but depres-
sion and anxiety are also common (154,164,165). PDD and DLB characteristically 
display high levels of psychotic symptoms such as delusion or hallucinations, with 
as much as 80% of patients showing symptoms of visual hallucination (166,167).
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Studies have shown that approximately 80% of MCI patients display NPS, with 
depression being the most common manifestation (155). Furthermore, NPS is 
thought of as one of the earliest signs of preclinical AD, and presence of NPS in 
MCI is associated with increased risk of developing AD as well as other dementia 
subtypes (168,169). Additionally, the presence of any clinically significant NPS 
in patients, who have already developed AD, are associated with more rapid pro-
gression to severe dementia and increased mortality (136,138). Therefore it has 
been proposed that treatment of NPS could possibly decrease the incidence and 
progression of AD (136,138). Several studies have also shown that the presence 
of NPS, such as depression or anxiety, in cognitively healthy elderly increases the 
risk of developing cognitive impairment and eventually dementia (170–173). This 
implies that NPS are a potential clinical marker for the probability of progression 
from asymptomatic preclinical dementia to manifest neurodegenerative disorder.
Since the presence of NPS has been associated with increased risk of dementia 
development, even in the absence of cognitive impairment, researchers have 
proposed “mild behavioral impairment” (MBI) as a diagnostic entity (130,174). 
MBI is defined as mild functional impairment due to NPS, persisting for more 
than six months, and can be diagnosed simultaneously as MCI or as a standalone 
diagnosis (174). Due to the fact that neurodegenerative disorders can debut with 
NPS preceding symptoms of cognitive decline, the aim of the MBI diagnostic 
entity is to identify elderly patients with newly developed behavioral symptoms 
in the spectrum of neurodegenerative diseases. These patients have historically 
often have been misdiagnosed with psychiatric disorders, potentially providing 
a possibility for early detection and management of underlying dementia (174).
1.2.3 Treatment of NPS
• Non-pharmacological treatment
The first line of treatment for NPS is focused on non-pharmacological interven-
tions such as management of physical diseases, pain, psychosocial determinants 
or other factors which might contribute to the presentation of symptoms in the 
individual patient (175–177). Specific interventions include, for example, envi-
ronmental manipulation, cognitive training, acupuncture, physical exercise, aro-
matherapy or music therapy (133,177). For instance, environmental manipulation 
aims at reducing potential stressors in patient surroundings, as well as providing 
activities and creating set routines, hopefully resulting in less NPS burden (133). 
Naturally, a key component in general treatment strategies for NPS includes man-
agement of other medical conditions such as pain, urinary tract infections, anemia 
or hyperglycemia, which are frequent in patients with dementia displaying NPS 
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and often underdiagnosed (178). Overall, the results from studies investigating the 
effectiveness of non-pharmacological treatment options show that these interven-
tions are safe and show small but positive effects, although not all studies have 
been able to identify  statistically significant results (176).
Currently, the most validated non-pharmacological treatment options include 
interventions provided by family members aimed at identifying  modifiable 
risk factors for NPS, with one meta-analysis indicating effect sizes at least 
as good as drug treatments for behavioral symptoms in dementia (179). 
However, although these interventions are recommended by most experts world-
wide, as the first line of treatment, they have not become routine in most health care 
systems which can probably be attributed to several factors, including inadequate 
competence among physicians as well as economic incitements (177).
• Pharmacological treatment
Several different classes of drugs have been studied and are currently used in clini-
cal practice to reduce NPS. Still, there are to this day few medications approved 
by the American Food and Drug Administration (FDA) for treatment of behavioral 
symptoms in dementia, and most prescriptions are conducted on an off label basis 
(133). The most frequently used medications for pharmacological treatment of NPS 
include acetylcholinesterase inhibitor (AChEI), antipsychotics, mood stabilizers, 
NMDA-receptor modulators, benzodiazepines and antidepressants, but results 
regarding their efficacy have been inconsistent, and their use is often associated 
with significant side effects for the patients (133,180,181). Pimavanserin, an atypi-
cal antipsychotic, is approved by the FDA for treatment of psychotic symptoms 
in Parkinson’s disease dementia (182). 
Earlier reviews investigating the efficacy of pharmacological treatment for NPS 
have suggested the use of selective serotonin reuptake inhibitors, e.g. antidepres-
sants, for depression specifically, but they do not seem to have any value when 
used for other types of NPS (183). Benzodiazepines are not recommended with 
the exemption of treating short term anxiety (183). Data from a meta-analysis 
indicates that in general, AChEIs and atypical antidepressant, are the only phar-
macological interventions showing modest but statistically significant beneficial 
outcomes on overall NPS burden, with reduced total scores on the neuropsychiatric 
inventory (NPI) (184). However, this must be balanced against the increased risk 
of adverse events when considering the use of these medications in the dementia 
population (184). 
Recently, more evidence is emerging regarding the possible severe side effects 
associated with the use of antipsychotics in patients with dementia. Several 
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 studies have shown that the use of antipsychotics in this patient group is associ-
ated with both more rapid deterioration of cognitive function, as well as increased 
overall mortality (185–187). Due to these findings, the FDA has issued a “black 
box” warning for the use of antipsychotics in the dementia population, citing 
an increased risk of mortality and cerebrovascular events (188). Despite these 
warnings, antipsychotics are still frequently prescribed for NPS (188). Currently, 
AChEIs are recommended as the first line of choice for patients with mild to 
moderate symptoms, whereas antipsychotics should be reserved for patients with 
more severe NPS (184). Since current medications display modest efficacy at best 
and are associated with significant side effects, researchers have been searching 
for new potential treatment options. A few recent studies have suggested can-
nabinoids can be used as a potential treatment for agitation in dementia. Despite 
these trials showing promising effects as well as good tolerability, the data is still 
very limited (189–192).
1.2.4 Pathophysiology of NPS
The etiology of NPS in dementia is currently not established but is likely a conse-
quence of complex interaction between neurobiological, genetic and environmental 
factors (1,131,180,193). Current combined knowledge from CSF, neuroimaging and 
neuropathological studies suggest that the etiology of different NPS is associated 
with region-specific cerebral alterations, rather than a diffuse brain pathology (193). 
It is crucial to have a conceptual model of the involved mediators to understand 
the pathological mechanism associated with NPS, and a previous review from 
Geda et al. (194), has proposed three theoretical frameworks for neuromodulation 
of behavior important to NPS. 
Firstly, the frontal-subcortical circuit model suggests that at minimum three circuits 
connecting frontal and subcortical brain areas modulate behavior, including the 
dorsolateral circuit for planning or executive functions, the orbitofrontal circuit 
involved in inhibitory control and social functioning, as well as a circuit controlling 
motivated behavior. Secondly, the cortico-cortical network model hypothesizes 
that five different partially overlapping cortical networks govern complex behav-
ior. Lastly, the monoaminergic model postulates that dopaminergic, serotonergic 
and noradrenergic neurons in the brainstem mediated human behavior through 
axonal projections to various areas of the brain (194). Additionally, the associa-
tion between NPS and underlying dementia pathology can be conceptualized in 
different ways. NPS can be thought of as a direct consequence of the pathology 
caused by the underlying neurodegenerative disease (194). Albeit, earlier research 
has also proposed that NPS could precede and contribute to the development of 
neurodegeneration in the setting of AD, or have separate etiologies with synergistic 
effects, thus promoting dementia development (194). 
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1.2.5 Cerebrospinal fluid biomarkers
• “Core AD biomarkers”
As previously described, cerebral protein accumulation resulting in amyloid 
plaques and neurofibrillary tangles combined with synaptic dysfunction and neu-
ronal death, constitute the main pathological hallmarks of AD (25). Biomarkers 
reflecting these AD-associated neuropathological changes can be measured in-
vivo using CSF levels of total-tau (T-tau), phosphorylated-tau (P-tau) and the 42 
amino acid isoform of β-amyloid protein (Aβ1-42), often referred to as “core-AD 
biomarkers” (195). CSF T-tau is a marker for cortical axonal degeneration and 
disease intensity, while P-tau reflects cerebral tangle pathology and Aβ1-42 is asso-
ciated with the cerebral amyloid burden (196,197). These biomarkers can be used 
to assess the ongoing neurodegenerative process and typically display different 
profiles depending on the specific underlying neuropathological condition (198). 
For example, AD patients show increased levels of T-tau, P-tau and decreased 
levels of Aβ1-42 in CSF, as compared to healthy controls, corresponding to high 
overall levels of neurodegeneration and increased amounts of neurofibrillary tan-
gles and amyloid plaques (198). 
These biomarkers are used in the clinical setting facilitating correct differentiation 
between various dementia subtypes by increasing the diagnostic accuracy, and 
can also be used to identify prodromal AD in MCI patients with a specificity and 
sensitivity of 83 – 95 %, depending on the study cited (42,199,200). Furthermore, 
the ratio of Aβ42:Aβ40 is often used in the clinical setting, as it normalizes Aβ1-42 
levels for total Aβ production, and thereby increases diagnostic accuracy (201). 
Due to the complexity and heterogeneity of dementia pathology, there is still a 
need for more ways to objectively quantify and asses other disease mechanisms 
at play. Thus, novel biomarkers are constantly being researched. Recently, mark-
ers for synaptic and axonal degeneration have become of interest, including neu-
rogranin (Ng), growth-associated protein 43 (GAP-43) and neurofilament light 
protein (NFL) (195,202).  
• Biomarkers for synaptic and axonal degeneration
Ng, a dendritic postsynaptic protein primarily located in cortical and hippocam-
pal neurons involved in synaptic plasticity and long-term potentiation, has been 
suggested as a potential biomarker candidate reflecting synaptic dysfunction and 
degeneration in the setting of AD-pathology (195,203). Previous neuropathologi-
cal autopsy studies have indicated that in the temporal and parietal cortex of AD 
patients, the full-length Ng protein is reduced, while cleavage of Ng into smaller 
peptides is increased (204). This results in the leakage of those Ng peptides into 
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CSF thought to mirror synaptic degeneration. CSF studies of Ng have demonstrated 
that Ng is increased in AD and MCI-AD compared with both healthy controls and 
other neurodegenerative disorders, thus indicating specificity for AD and a poten-
tial discriminatory role of this biomarker enabling increased diagnostic accuracy 
(203,205–207). A recent meta-analysis indicated that CSF Ng differs significantly 
between AD and healthy controls, but no difference could be observed between 
AD and LBD or FTD patients (208). Additionally, Ng has been shown to correlate 
with both amyloid and tau pathology, suggesting a link between core AD pathol-
ogy and synaptic dysfunction (207,209,210).
In patients with MCI, high baseline levels of CSF Ng have also been associated 
with low cognitive function as well as longitudinal deterioration, and Ng seems 
to predict conversion from MCI to AD (205,211–213). High levels of CSF Ng in 
healthy patients has also been shown to predict inferior memory function and cor-
relate to grey matter volume loss in the precuneus (214,215). Studies have shown 
that the ratio between neurogranin and BACE1 in CSF is correlated to the rate 
of cognitive deterioration in both preclinical AD, MCI and AD, while also being 
helpful in correctly differentiating AD from depression in patients with similar 
cognitive profiles (216–218). This has important clinical value since earlier research 
has demonstrated that amongst elderly diagnosed with a primary psychiatric dis-
order, 20% actually display a CSF biomarker profile compatible with AD (219). 
This highlights the importance of both novel biomarkers for different pathological 
mechanisms, and the consideration of NPS as a potential early manifestation of 
dementia, rather than an isolated psychiatric condition.
GAP-43 is an intracellular protein present exclusively in neurons showing high 
density primarily in axon terminals, thought to be involved in post-injury neuronal 
sprouting and regeneration, as well as axonal growth and plasticity (220). Previous 
neuropathological autopsy studies of AD patients have indicated that GAP-43 levels 
are significantly decreased, as compared to healthy controls, in the frontal cortex 
and some areas of the hippocampus, while other hippocampal regions display static 
or even increased GAP-43 activity (221–223). These findings are interpreted as 
a sign of synaptic dysfunction and degeneration in regions with reduced levels of 
GAP-43, and aberrant sprouting in brain regions with increased GAP-43 (221–223). 
Most CSF studies have indicated that GAP-43 levels are increased in AD as com-
pared to both healthy controls and other dementia diseases, although one study 
has indicated decreased GAP-43 levels in patients with dementia as compared to 
healthy controls (224–227). Additionally, increased CSF GAP-43 has been cor-
related with both cognitive decline and increased tau and amyloid pathology in 
several brain regions such as amygdala, cortex and hippocampus, and low GAP-43 
in the frontal cortex has been associated with increased NFT burden in patients 
with AD (227,228). 
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NFL belongs to a group of structural cytoskeletal components denoted as class 
IV intermediate filaments, primarily distributed in large myelinated axons, with 
a pivotal role in maintaining the stability of axons as well as radial growth (229). 
NFL increases both in CSF and blood in the presence of neuroaxonal damage 
independently of on the underlying pathological mechanisms, whether it be inflam-
mation, neurodegeneration or vascular morbidity, thus making NFL a general 
marker for overall axonal neurodegeneration (230). Indeed, increased CSF NFL is 
associated with both increased overall mortality and diseases severity in dementia, 
and correlate with a faster rate of cognitive decline as well as brain atrophy in 
AD (231,232). Both AD and MCI patients show increased CSF NFL compared to 
healthy controls (231–237). Some interdiagnostic differences have been observed 
with dementia disorders affecting primarily subcortical brain areas, such as VaD, 
displaying increased CSF NFL levels (231–237). 
In general, the knowledge regarding the association between NPS and core-AD 
pathological features as well as synaptic and axonal dysfunction is not clearly 
established. Albeit, some animal, imaging, autopsy and CSF studies have tried to 
examine these relationships. 
1.2.6 Pathophysiology of NPS associated behavioral dysfunction
• Animal models
Several animal models using transgenic APP/PSEN1 mice resulting in increased 
production of β-amyloid and rapid progression of amyloid neuropathology, 
including the formation of APs, have been shown to display enhanced aggression, 
disinhibition and altered motor activity relative to wild type controls (238–240). 
Thus, indicating the potential role of amyloid pathology in behavioral symptoms 
of NPS. Additionally, the silencing of specific serotonergic neurons in rodent 
brains generates increased levels of aggression (241), suggesting that the neuro-
degenerative process affecting these neurons could be associated with behavioral 
dysfunction in dementia. 
• CSF studies
Few CSF studies have examined the associations between levels of core AD-pathology 
biomarkers and behavioral symptoms, but some evidence for their association exists, 
although the data is somewhat inconsistent. One CSF study found negative corre-
lations between Aβ1-42 and aggressive behavior in AD patients, thus implying an 
association between amyloid pathology and behavioral symptoms (242). However, 
results from other studies contradict these findings (243). Agitation and irritability 
have also been correlated with abnormal levels of CSF Aβ1-42 in MCI patients, 
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and negative correlations between the total amount of NPS and Aβ1-42 have been 
observed, suggesting an association between amyloid pathology and NPS sever-
ity (244,245). Baseline abnormalities in CSF core AD biomarkers have also been 
demonstrated to predict the development of behavioral and mood type symptoms 
in cognitively healthy elderly, suggesting an association with AD type pathology 
(246). One CSF study of neurotransmitters found that in FTD patients, dopamin-
ergic dysfunction, including increased neurotransmission and impaired modulation 
of dopaminergic transmission by serotonergic neurons, is associated with agitation 
and aggressive behavior (247). Additionally, alterations in glutamate transmission 
have also been associated with agitated behavior in FTD (248). 
• Autopsy studies
The largest autopsy study to this date including 455 patients with pure AD pathol-
ogy showed significant associations between several NPS, including behavioral 
dysfunctions such as agitation, and NFT burden, while no association of NPS 
to amyloid burden was identified (249). Given our current understanding of the 
cerebral regulatory mechanisms governing agitation, thought to be in part medi-
ated by noradrenergic neurons in the LC, coupled with recent research indicat-
ing the presence of hyperphosphorylated-tau and α-synuclein inclusions in this 
area as one of the earliest pathological findings in AD and PDD respectively, 
generates a hypothesis implicating early tau-mediated pathology in subcortical 
regions affecting neurotransmission of monoaminergic pathways such as the 
noradrenergic as a potential culprit in the development of agitation (95,249–251). 
This hypothesis is also supported by the fact that NPS often precedes cognitive 
decline, which is in line with the observed early neurodegeneration in subcorti-
cal regions rather than cortical areas more responsible for cognition (95,249). 
Other smaller autopsy studies have indicated that agitation/aggressive behavior is 
correlated with increased levels of phosphorylated-tau in the frontal and parietal 
cortex (252) as well as increased amounts of neurofibrillary tangles in the hip-
pocampus, orbitofrontal and anterior cingulate cortex (253,254). 
Several post mortem studies have also indicated that agitation is associated with 
the altered cholinergic and serotonergic transmission, especially in the temporal 
and frontal cortex as well as hippocampus (255–258). Upregulation of serotonin 
re-uptake sites in the hippocampus has also been shown to correlate with aggres-
sive behavior in AD patients (259). Of interest, presence of neurofibrillary tangles 
and to a lesser extent amyloid plaques, resulting in neurodegeneration and loss of 
serotonergic and cholinergic neurons in the nucleus raphe and nucleus basalis of 
Meynert, with projections to the frontal cortex are associated with the core neu-
rodegenerative process of AD (56,260). 
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• Imaging studies
Neuroimaging studies of cerebral amyloid depositions, using 18F-Florbetapir-
Positron emission tomography (PET), have shown that irritability is associated 
with increased amyloid burden in the parietal cortex amongst patients with AD 
(261). Studies of structural abnormalities have demonstrated associations between 
agitation, aggression or disinhibition and gray matter atrophy of specific brain 
regions including the frontal cortex, anterior cingulate cortex (ACC), posterior 
cingulate cortex (PCC), insula, amygdala and hippocampus, including regions of 
the salience network (262–265).
Hypoperfusion in regions such as left anterior temporal and right parietal cortex 
as well as low metabolic activity in the frontal, temporal and cingulate cortex 
have also been associated with agitation in AD (266–268). Agitation in EOAD 
has been linked to increased glucose metabolism in frontal and limbic structures, 
and greater resting-state functional connectivity in the anterior salience network 
has been associated with behavioral symptoms in AD (269,270). Furthermore, 
one longitudinal study of patients with preclinical AD showed that high levels 
of NPS, including irritability at baseline, were associated with increased glucose 
uptake in the PCC, ventromedial prefrontal cortex, and right anterior insula, pre-
dicting subsequent hypometabolism in the PCC after two years (271). Decreased 
cholinergic receptor binding in the ACC has also been associated with agitated 
behavior in AD (272).
Overall, current evidence suggests that behavioral symptoms in AD are associated 
with pathological changes in both structure and function of specific brain regions, 
including the frontal cortex, ACC, insula and amygdala, involved in the regulation 
of human behavior and salience, while also implicating that the neurodegenerative 
process affecting monoaminergic pathways from subcortical regions is involved in 
the presence of behavioral symptom in dementia (1,249,273). Furthermore, there 
seems to be an overlap between the core features of AD-pathology and regions 
associated with agitation, suggesting a possible link between the two (273).
1.2.7 Pathophysiology of NPS associated mood disorders
• Animal models
Transgenic APP/PSEN1 mouse models have been shown to display apathy and 
depression-like symptoms, suggesting a potential role of amyloid pathology in 
the generation of mood symptoms in AD (274–276). Transgenic mice generating 
pronounced AD pathology displaying depression-like symptoms have also been 
demonstrated to have lower levels of the neurotransmitters serotonin, noradrenaline 
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and dopamine in the frontal cortex and ventral hippocampus (277). These areas 
are heavily affected by AD pathology and involved in the regulation of behavior, 
thus providing a link between depression and AD pathology. Additionally, animal 
models overexpressing β-synuclein mimicking LBD display increased levels of 
depression-like behavior as compared to wild type mice (278).
Transgenic mice generating AD pathology of both amyloid and tau type, display 
increased behaviors such as restlessness or freezing, which are interpreted as 
increased levels of anxiety (279). Alterations in cholinergic transmission have also 
been proposed as a mediator of anxiety in AD mouse models (280) and hypoactivity, 
which is thought to be a representation of AD induced apathy, has been reported 
(281). Increased levels of anxiety have also been demonstrated in animal models 
of vascular pathology (282) as well as in APP knock-in mouse models (283,284). 
• CSF studies
Some studies have investigated the association between mood disorders and core 
AD CSF biomarkers, but generally few publications are available, and the results 
are inconsistent. Apathy has been shown to correlate with high levels of P-tau in 
patients with AD (243), whereas depression has not been found to correlate with 
biomarkers reflecting core AD-pathology (243,285). Anxiety in MCI patients has 
in one study been associated with low levels of Aβ42, whereas depression and 
apathy did not display any correlations with core AD biomarkers (244). A study of 
CSF neurotransmitters has also indicated that low levels of CSF Taurine are associ-
ated with depression as well as total levels of NPS in AD, while the ratio between 
dopamine and serotonin metabolites is associated with anxiety (248). Abnormal 
CSF levels of core AD biomarkers at baseline in cognitively healthy elderly, have 
also been shown to predict future development of mood disturbances, including 
depression and anxiety (246,286). CSF core AD biomarkers can also be used to 
facilitate differentiation between late-life depression, which is very common, and 
AD-associated depression (287). Additionally, CSF studies have indicated associa-
tions between mood disorders and neuroinflammation in AD (288).
• Autopsy studies
Autopsy studies have indicated increased amyloid and tangle burden in the hip-
pocampus amongst patients with AD and a history of depression during life-
time (289). Increased cortical tangle burden has been observed in patients with 
AD and comorbid depression, as compared to AD patients without depressive 
symptoms, implying an interaction between AD pathology and depression (290). 
In the largest autopsy study to this date, mood disorders including depression and 
apathy showed, similarly to behavioral symptoms, clear associations with early 
neurofibrillary tangle pathology, whereas no associations between mood  alterations 
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and amyloid pathology where found in patients with pure AD (249). Presence of 
apathy has also been associated with an increased amount of neurofibrillary tan-
gles in the ACC in patients with AD (291). 
Depression has also been linked to neurotransmitter alterations, with one 
study showing that selective loss of serotonergic receptors in the hip-
pocampus is associated with increased depressive behavior (259). 
Loss of noradrenergic neurons in LC and serotonergic neurons in the nucleus of 
raphe have also been associated with depression, and the degeneration of serotoner-
gic neurons is thought to be more severe amongst patients with AD and depression, 
compared to the general loss of serotonergic neurons seen in AD (1). However, 
some autopsy studies have failed to replicate these results, and instead imply that 
pathological alterations in glutamatergic neurotransmission are a potential culprit 
(292). These findings, combined with the evident therapeutic resistance of dementia 
associated depression to SSRI treatment, challenges the monoaminergic hypothesis 
as the cause of depression in cognitive impaired elderly (292). Instead, abnormali-
ties in gamma-aminobutyric acid (GABA) and glutamate transmission have been 
proposed to be involved. Studies indicate that decreased levels of GABA, increased 
levels of GABAA-receptors, as well as increased levels of glutamate in the frontal 
cortex are associated with depression in dementia (292,293).
• Imaging studies
PET studies using Pittsburgh Compound-B (PIB), a ligand for β-amyloid, have 
shown associations between increased amyloid burden and presence of depression 
in MCI patients, suggesting depression as a risk factor or early manifestation of 
AD (294). Another PET study on MCI patients, using a ligand for both amyloid 
and tangle pathology, showed that severity of depression and anxiety is associ-
ated with increased AD type pathology in the lateral temporal cortex and PCC 
respectively (295). Depression has also been associated with reduced grey matter 
volumes in the left middle frontal cortex and entorhinal cortical thickness, as well 
as accelerated atrophy in ACC (262,296).
AD patients with apathy have also been demonstrated to display increased amy-
loid burden in the frontal and right anterior cingulate cortex, as compared to AD 
patients without apathy (297). Similarly, apathy has been associated with increased 
cortical amyloid burden in MCI patients (298), and a recent review indicates that 
in general imaging abnormalities associated with apathy predominantly affect 
brain regions between the frontal cortex and basal ganglia (299). One PET study 
has indicated that tau-associated pathology promotes focal neurotoxicity in the 
orbitofrontal cortex generating apathy in AD patients (300). Atrophy of brain 
regions involved in arousal and reward processing, such as the prefrontal and 
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cingulate cortex, have been associated with apathy in AD (301,302). Interestingly, 
one fluorodeoxyglucose (FDG)-PET study has indicated that apathy is associated 
with different neuroanatomical sites in AD as compared to behavioral FTD (303). 
Additionally, one imaging study has suggested that reduced dopamine transporter 
uptake in putamen is associated with apathy in dementia (304). 
1.2.8 Pathophysiology of NPS associated psychotic symptoms
• Animal models
There is currently limited data on animal models for psychotic symptoms in demen-
tia. To this date, only one study using animal models of dementia pathology has 
investigated the association between psychotic symptoms and the neurodegen-
erative process associated with dementia (305). Transgenic mice generating tau-
type pathology in frontal cortex and hippocampus displayed correlations between 
psychotic phenotype and insoluble P-tau, suggesting a link between tau mediated 
neurodegeneration and psychosis in AD (305).
• CSF studies
CSF studies have also indicated the contribution of tau-associated neurodegenera-
tion in psychotic symptoms of AD. One longitudinal CSF study on AD patients 
has shown that high levels of T-tau at baseline, but not P-tau and Aβ1-42, were 
associated with an increased probability of developing psychotic symptoms (306). 
Levels of CSF dopamine metabolites have also been shown to exhibit a negative 
association with hallucinations in DLB patients (248).
• Autopsy studies
In line with animal and CSF studies, psychotic behaviors have been associated with 
a higher burden of tau pathology. In one study, patients with AD and psychotic 
symptoms had a more than a twofold increase of neocortical NFTs, as compared 
to AD patients without psychotic behavior (307). Similarly, one study has indi-
cated that psychotic AD patients have increased concentrations of intraneuronal 
P-tau in the prefrontal cortex, as compared to non-psychotic AD patients (308). 
Of interest, in one autopsy study, the associations between high levels of P-tau 
in the frontal cortex and psychotic symptoms was only observed in female AD 
patients, whereas in males psychotic behavior was associated with α-synuclein 
pathology (309). Cholinergic alterations have also been proposed to be involved, 
with increased density of muscarinic receptors in the frontal and temporal cortex 
displaying an association with psychotic symptoms in AD (310). Increased D3 
receptor density in nucleus accumbens has also been associated with psychosis in 
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AD (311). Reduced levels of serotonin, as well as the ratio between serotonin to 
acetylcholinesterase, have also been associated with psychosis in AD (256,312). 
Additionally, increased cortical β-amyloid (1-42)/β-amyloid (1-40) ratio has been 
correlated with psychosis in AD, suggesting a role of soluble forms of Aβ in the 
pathogenesis of psychosis in AD (313).  
• Imaging studies
Imaging studies using PET have shown that alterations in dopamine transmission, 
including increased D2/D3 receptor availability in the striatum, are associated with 
delusions in AD (314). Neuroimaging studies have demonstrated that psychosis 
in AD is associated with decreased perfusion, hypometabolism and reduced grey 
matter volume in areas such as the frontal cortex and ACC. However,  these results 
are somewhat inconsistent (273,315). Additionally, the atrophy rate of the fron-
tal cortex, parietal cortex and ACC has been associated with manifest psychotic 
symptoms during longitudinal follow-up (316). 
Figure 5. Brain areas associated with NPS. FC = frontal cortex, ACC = anterior cingulate 
cortex, AMY = amygdala, HC = hippocampus
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1.3 Clinical measurements of NPS and cognition
Assessment of NPS is usually conducted through one on one interviews between 
health care providers and patients, or the patient’s relatives and caregivers, using dif-
ferent clinical rating scales. Correct measurement and description of NPS constitutes 
a foundation for both research and clinical practice in this area. Several different 
measurement scales have been developed for this purpose. The Neuropsychiatric 
Inventory (NPI) is currently considered the gold standard for measurement of 
NPS and is one of the most validated rating scale used in modern medical prac-
tice (317). In the studies included in this thesis, the NPI was used to assess both 
overall levels and subtypes of NPS. Additionally, the Cohen-Mansfield agitation 
inventory (CMAI) was used to specifically asses levels of agitation and aggres-
sive behaviors (318).
1.3.1 Neuropsychiatric Inventory
The NPI is globally the most used tool to assess NPS in dementia, and several 
versions have been developed and translated into multiple languages (319). The 
most prevalent version of NPI consists of 12 different domains assessing vari-
ous NPS including; hallucinations, delusions, agitation/aggression, dysphoria/
depression, anxiety, irritability disinhibition, euphoria, apathy, motor disturbance 
as well as changes in night-time behavior or appetite and eating patterns (320). 
The NPI is a structured interview which is completed by a trained clinician inter-
viewing an informant, in most cases, the patient’s caregiver or other relatives 
familiar with the patient. The NPI includes 12 items and assesses both frequency 
and severity of symptoms as well as caregiver distress. Every domain is scored 
based on frequency (1-4 points) and severity (1-3 points) of NPS during the last 
month, and the scores are then multiplied do give a total domain score of maxi-
mum 12. The total score is then obtained by adding the individual domain scores, 
allowing a minimum of 0 and a maximum of 144 points on the NPI scale. In both 
research and clinical practice, the total NPI score (0-144) and domain-specific 
scores (0-12) are used. 
1.3.2 Cohen-Mansfield Agitation Inventory
The CMAI is a questionnaire for the assessment of agitation in dementia and is 
administered by health care professionals with the patient’s caregivers. CMAI 
consists of 29 items describing different emotional and behavioral disturbances, 
specifically related to agitated behavior (318). Every item is rated based on fre-
quency 1-7, with 1 being never and 7 corresponding to the presence of agitated 
behavior on an hourly basis, with higher scores thus reflecting increased agitation. 
The total CMAI score is then calculated as the sum of the 29 different frequency 
scores, with a maximum score of 203 points. 
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The results from the CMAI questionnaire can be assessed as the total sum (CMAI-
total) or divided into four different cluster-scores relating to different subtypes 
of agitation. Sub-item 1 measures aggressive physical behavior such as kicking 
or hitting. Sub-item 2 measures non-aggressive physical behavior including, 
for example, pacing, hoarding or general restlessness. Sub-item three measures 
aggressive verbal behavior such as screaming or cursing, while sub-item 4 meas-
ures non-aggressive verbal behavior, including symptoms such as complaining 
or negativism. The cluster-scores are not considered as distinct entities but rather 
as different manifestations of agitation. Both the CMAI-total score and the four 
cluster scores were used in the statistical analysis in this thesis.
1.3.3 Mini Mental State Examination
Several different clinical tests intended to measure cognitive function and decline 
in the context of dementia have been developed. These tests assess different cog-
nitive domains such as executive functioning, memory or visuospatial abilities. 
They are often used as screening tools for dementia amongst patients presenting 
with memory complaints or other symptoms, indicating the possibility of demen-
tia. In Swedish healthcare, the most commonly used screening tool for cognitive 
impairment is the Mini Mental State Examination (34), although other tests such 
as the MoCA are also often used (33). A recent Cochrane review has shown that 
the sensitivity and specificity of MMSE for detecting dementia is 0.85 and 0.90, 
respectively (321). In this thesis, MMSE was the primary tool for quantification 
of cognitive status. 
MMSE is a clinician-administered test that can be used for the assessment of cogni-
tive function in dementia, or when screening for cognitive impairment in patients. 
It is also suitable for the assessment of dementia stages and disease progress. The 
test consists of 20 different tasks or questions, designed to identify impairment 
in 11 specific cognitive domains such as memory, executive functions or orien-
tation. The maximum score is 30 points, and a result of 24 or less is considered 
pathological and potentially indicative of dementia. Although, it is important to 
consider that patients with high cognitive capabilities at baseline may experience 
significant cognitive impairment while still score within the normal range on 
MMSE, suggesting the need for higher cut off scores in patients with high edu-
cation (322). Other relevant rating scales in the context of dementia include the 
Clinical Dementia Rating scale, which assesses cognitive functioning but also 
aspects of ADL, or the Cornell scale for depression in dementia for quantification 




The overall aim of this thesis was to study the relationship between neuropsychi-
atric symptoms in dementia and core CSF AD biomarkers (Aβ1-42, T-tau, P-tau), 
as well as biomarkers for synaptic and axonal injury (Ng, GAP-43 and NFL). 
Secondary aims included investigation of the effect of current treatment options 
on NPS and CSF biomarker profile.
The primary aims, according to the study, were:
• Study I: To examine the association between core AD biomarkers and 
agitation in dementia.
• Study II: To compare treatment effects between Galantamine and 
Risperidone on agitation in people with dementia.
• Study III: To investigate the effect of Galantamine and Risperidone on 
the core AD CSF biomarker profile. 
• Study IV: To examine the association between Ng, GAP-43 and NFL in 
CSF and neuropsychiatric symptoms in dementia.  
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3 MATERIALS AND METHODS
3.1 Ethical approval
Informed consent was obtained from all patients or if necessary, the patients’ legal 
representative. The regional Ethics Committee of Karolinska Institutet, Stockholm 
Sweden, approved the study. Registration number: 441/01 at Karolinska Institutet.
3.2 Study population
Data from two different study populations have been included and used in the papers 
constituting this thesis. The predominantly used dataset (study I to IV) comes from 
patients originally included in a randomized controlled trial to compare the effect 
of Galantamine and Risperidone on NPS in dementia (325). This patient cohort 
is included in all four papers and will be referred to as the NPS-cohort. In the 
fourth and last paper, an additional patient group was sampled from the GEDOC 
database at Karolinska University Hospital to obtain healthy controls as well as 
AD patients with low levels of NPS. This study population will be referred to as 
the GEDOC-cohort.
3.2.1 Inclusion and exclusion criteria
• NPS-cohort
One hundred and forty-five community-dwelling patients, referred from general 
practitioners to the memory clinic at the Department of Geriatric Medicine at 
Karolinska University, due to suspected dementia and presence of NPS between 
January 2003 and September 2005 were available for inclusion. Out of the referred 
patients 100 of age 45 or older, who fulfilled the criteria according to the Diagnostic 
and statistical manual of mental disorder, Fourth Edition (DSM-IV) (326) for 
diagnosis of AD with behavioral disturbance, VaD with behavioral disturbance, 
MIX with behavioral disturbance, PDD with behavioral disturbance, FTD with 
behavioral disturbance or presence of MCI were included in the study. For inclu-
sion, patients also had to have a total score of at least 10 on the NPI with symptoms 
present during the last two weeks. Patients were excluded if they had a diagnosis 
of schizophrenia or other psychiatric disorders, a history of seizures, alcohol abuse 
and clinically significant hepatic, renal, pulmonary or metabolic disturbances. 
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Figure 6. Flowchart for NPS-cohort
• GEDOC-cohort
GEDOC is a research database and biobank at the memory clinic, Karolinska 
University Hospital, including clinically well-characterized patients assessed for 
dementia due to memory complaints at the clinic. The database contains infor-
mation regarding different variables such as diagnosis, CSF biomarkers, MMSE 
scores as well as CSF samples, created to facilitate research in the field of demen-
tia. A total of 60 patients, assessed between 2003-2015, were recruited from the 
GEDOC database out of a total of 13300 existing subjects in the system. Thirty 
of these patients were diagnosed as subjective cognitive impairment (SCI), with 
normal MMSE scores and normal CSF AD-biomarker profile, defined as Aβ1-42 
> 500, T-tau <400, P-tau <80 ng/ml. These patients were referred due to subjec-
tive memory complaints but assessed as cognitively intact with no evidence of 
neurodegenerative disorder, and thus included and treated as healthy controls. 
Additionally, thirty patients diagnosed with AD displaying an AD positive bio-
marker profile, i.e. Aβ1-42 < 500, Tau >400 and P-Tau >80 ng/ml, but without 
neuropsychiatric symptoms and an MMSE score equal or more than 16 but less 
than 24 were included. Patient’s medical records were reviewed, and subjects 
were excluded from the study if any significant NPS were mentioned. This patient 
subgroup is referred to as the “AD low NPS” group (Figure 7).  
39
Figure 7. Flowchart for GEDOC-cohort
3.2.2 Clinical assessment
• NPS-Cohort
After inclusion, all patients underwent baseline evaluation of neurological, physi-
cal, behavioral and neurocognitive status, which was repeated during follow-up 
after 3 and 12 weeks. Initial diagnostic procedures included somatic, psychiatric, 
neurological and neuroimaging (computed tomography scans) examination per-
formed by a licensed specialist in geriatric medicine with experience in dementia. 
Lumbar puncture for collection on CSF was conducted at baseline and after 12 
weeks. During each visit, a medical examination including psychiatric and neuro-
logical status was conducted, and standardized scales of cognition (MMSE) and 
neuropsychiatric symptoms (NPI, CMAI) were administered, in each instance 
by the same specialist in geriatric medicine (YFL). One hundred patients were 
included with the following distribution of dementia diagnoses; 34% AD, 27 % 
MIX, 18 % VaD, 3 % FTD, 2 % PDD, 4 % unspecified dementia and 12 % MCI.
• GEDOC-Cohort
Patients in the GEDOC-cohort were assessed by staff at the memory clinic, 
Karolinska University Hospital, according to standard operating procedures within 
Swedish health care. Data was collected from the electronic database, including 
variables such as diagnosis, CSF AD biomarkers, MMSE score, and NPI scores. 
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Frozen CSF samples from all patients were obtained. Due to insufficient data 
regarding rating scales for NPS (NPI) on the thirty included AD patients, their 
medical records were revived, and patients were excluded if significant mentions 
of NPS were observed. 
3.2.3 Randomization and intervention (NPS-cohort)
Included patients were consequently randomly allocated to one of the two treat-
ment groups according to a pre-defined randomization code. The initial dosage 
of Galantamine was 4 mg twice daily, increased to 8 mg twice daily after one 
week and to 12 mg twice daily at the start of week three. Subjects randomized to 
Risperidone treatment received 0.25 mg twice daily at the start. After one week, 
the dose was increased to 0.5 mg twice daily, and at the start of the week, three 
patients received 1.5 mg daily. Compliance was monitored by quantifying unused 
medication and via self-reports of patients and caregivers. To decrease bias, the 
study clinician performing the rating scales of NPS was unaware of the treatment 
arm at the time of clinical assessment.
3.2.4 Follow-up (NPS-cohort)
After initiation of the clinical trial, a total of nine patients dropped out during 
follow-up between baseline and week 12 (six patients in the Risperidone group 
and three patients in the Galantamine group). Reasons for withdrawal from the 
study as well as study design can be seen in Figure 6.
3.2.5 CSF analysis
• NPS-cohort
CSF samples were collected at baseline and after 12 weeks using standard operat-
ing procedures according to Swedish health care standards at the memory clinic, 
Karolinska University Hospital. Lumbar punctures were performed and the col-
lected CSF (6 ml) stored in polypropylene tubes. The first 2 ml of every sampling 
was discarded, and the rest was centrifuged at 3000 rpm for 10 min at 4C+ and 
frozen in aliquots of 2 ml at -70C. From the 100 included patients in the NPS-
cohort, 95 successful lumbar punctures were performed at baseline. This was 
because three patients refused the procedure, one had an arachnoid-cyst, and one 
sampling was unsuccessful due to muscular rigidity. The collected CSF was ana-
lyzed at the Department of Neurochemistry, Mölndal Hospital, by Kaj Blennow 
and collaborators.
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CSF T-tau concentration was determined using a sandwich ELISA (Innotest hTAU-
Ag, Innogenetics, Gent, Belgium) constructed to measure all tau isoforms regard-
less of phosphorylation status. Tau phosphorylated at threonine 181 (P-tau181) 
was measured using a sandwich ELISA method (INNOTEST® PHOSPHO-TAU, 
Innogenetics, Ghent, Belgium). Aβ1-42 levels were determined using a sandwich 
ELISA (INNOTEST® ß- AMYLOID (1-42), Innogenetics, Gent, Belgium) con-
structed to measure Aβ containing both the first and 42nd amino acid. These are 
commercially available ELISA kits frequently used in research for measurement 
of dementia biomarkers and validated through several studies (327–329), all tests 
were executed according to the manufacturer’s instructions. 
CSF levels of Aβ42 and Aβ40 to calculate the Aβ42/40 ratio were measured 
using the MSD Abeta Triplex assay (MSD, Rockville, MD), using a multiplexed 
method. CSF Ng was measured using an in-house ELISA method, as described 
previously in detail (207) using the monoclonal antibody NG2 (epitope 52–63) 
but with the monoclonal antibody NG22 exchanged for NG36 (both having the 
epitope Ng 63–75). CSF GAP-43 and NFL were analyzed by in-house ELISA 
methods as previously described in detail (227,330). All samples were analyzed 
by board-certified technicians, using one batch of reagents, following strict rules 
for quality control (331).
• GEDOC-cohort
CSF levels of Aβ1-42, T-Tau, P-Tau were obtained from the GEDOC database 
(n=60). These CSF samples were collected and analyzed using the same clinical 
producers and technical methods as for the NPS-cohort, and the same staff per-
formed lumbar punctures as in the NPS-cohort. Additionally, stored and frozen 
CSF samples from these patients were obtained and analyzed for levels of Ng, 
GAP-43 and NFL by the Department of Neurochemistry, Mölndal Hospital, using 
the same staff and methods as for the NPS-cohort. 
3.2.6 Statistical methods 
The majority of the investigated variables (CSF biomarkers) included in the four 
studies did not display normal distribution or equal variance. Therefore, in general, 
non-parametric statistics were used as the primary analytic method, but parametric 
methods were used when appropriate and considered acceptable due to sufficient 
sample size. Descriptive data are presented as medians and interquartile range (IQ) 
if not stated otherwise, and a p-value <0.05 was regarded as statistically signifi-
cant. The Statistica ® 10.0 (study I-III) and ® 13.0 (study IV) software package 
(StatSoft, Tulsa, Oklahoma, USA) was used for all statistical analysis. 
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Study I
In this study, we used Spearman rank correlations to investigate associations 
between baseline values of CSF AD-biomarkers (Aβ1-42, T-tau and P-Ttu) and 
CMAI, within the whole cohort and also within different diagnostic groups. 
Positive findings were then validated using a linear regression model adjusting 
for confounder’s age, gender and cognition (MMSE).
Study II
In this clinical trial, we primarily used repeated measures ANCOVA to compare 
the efficacy of Risperidone vs Galantamine on the main outcome variable total 
CMAI. Furthermore, we conducted dependent and independent T-tests to compare 
the within and between-group differences to strengthen the robustness of the results.
Study III 
In this study, we investigated the effect of treatment with Risperidone and 
Galantamine on the CSF profile of core AD-biomarkers. Dependent and inde-
pendent T-tests were used to compare between and within-group differences in 
biomarker levels post-treatment. We also created a general linear model including 
biomarkers, age, gender, dementia diagnosis and treatment type to see if any of these 
variables could predict a change in NPI or CMAI between the start and follow-up.
Study IV
In this study, we investigated the relationship between biomarkers Ng, GAP-43, NFL 
and NPS in dementia. Mann-Whitney U test was used to compare CSF biomarker 
levels between AD patients with high vs low NPS burden. Spearman rank correla-
tion test was used to assess the associations between biomarker levels and NPS. 
Factorial ANOVA was used to analyse differences in biomarker levels depending 
on diagnosis and APOE-status, as well as potential interaction effects. ANCOVA 
analysis was then performed to adjust for confounders, including age and gender. 
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4 SUMMARY OF RESULTS
4.1 Demographics
The baseline clinical and demographical characteristic of the study population from 
the NPS-cohort and GEDOC-cohort (SCI and AD low NPS groups) are presented 
in Table 1. The included patients were relatively equally distributed between the 
different diagnostic subtypes with regards to clinical characteristics, except for the 
expected higher MMSE score in MCI and SCI groups, as well as age which was 
substantially lower in the SCI group. In table 1, the nine patients diagnosed with 
FTD (n=3), PDD (n=2) and unspecified dementia (n=4) are compounded into one 
group denoted “Other” (n=9).



















Age, years 76(19) 78 (16) 80 (8) 70 (19) 60(7) 82 (7) 83 (6) 76 (9) 68 (21)
Females (n) 99 39 20 19 13 10 19 11 7
APOE-status  
ε4 pos / 
total n
78/149 37/54 24/34 13/20 7/29 4/12 14/27 10/18 6/9
MMSE 
0-30 points
22 (7) 20 (5) 20 (6) 21 (2) 30 (1) 26 (3) 20 (5) 22 (6) 16 (6)
NPI-total 
n=100
51 (39) 42 (29) 42 (29) m.d m.d 56 (48) 47 (52) 46 (26) 50 (33)
CMAI-total 
n=100
47 (17) 44 (15) 44 (15) m.d m.d 43 (20) 51 
(21)
45 (15) 48 (11)
Cornell 
n=144
4 (5) 4 (5) 5(5) 2 (5) 4 (4) 6 (5) 5 (4) 6 (4) 4 (1)


















P-tau pg/ml   
n=155  
90 (55) 98 (37) 87 (52) 104 (31) 45 
(18)
99 (48) 97 
(39)
74 (33) 66 (41)





















































































Data is presented as medians and IQR. Abbreviations; m.d = missing data, ADHNPS 
= AD high NPS, ADLNPS = AD low NPS. GEDOC-cohort includes the “AD low 
NPS” and SCI group. NPS-cohort incudes the “AD high NPS”, MCI, MIX, VaD 
and “other” group. AD total includes both the AD high and AD low NPS group.
4.1.1 Associations between CSF biomarkers and NPS
In study I, we found associations between agitation and high levels of P-Tau (r= 
0.35, p=0.05) and T-tau (r=0.36, p = 0.04) in patients with AD. No significant 
correlations were established when analyzing the whole cohort, nor in any of the 
other dementia subgroups, and no significant correlation was found between Aβ1-
42 and agitation. When adjusted for age, gender and MMSE-score, both P-tau and 
T-tau still displayed significant associations with CMAI-total in AD (p=0.04 and 
p=0.01 respectively). The analysis also showed that a one unit increase of T-tau 
results in a 0.008 increase in CMAI-total, while a one unit increase of P-tau was 
associated with a 0.11 unit increase on the total CMAI score.
In study III, when analyzing all patients, we found that low levels of CSF Aβ1-
42 at baseline was a significant predictor of change in irritability (Beta = -0.43, 
p < .05) during follow-up. Additionally, baseline levels of CSF Aβ1-42, Aβ42/40 
and P-tau were shown to be significant predictors of change in the NPI subitem 
assessing appetite and eating disturbances (Beta = 0.52, p < .05, Beta = -0.46, p 
< .05 and Beta = 0.32, p < .05 respectively).
In study IV, we did not observe any significant differences in CSF levels of biomark-
ers for synaptic (Ng, GAP-43) and axonal (NFL) injury between AD patients with 
high vs low levels of NPS when adjusted for age. Although, in patients younger 
than 70 years of age, a trend towards a statistically significant decrease of Ng in 
AD patients with high levels of NPS was observed as compared to AD patients 
with low levels of NPS (p=0.06, Mdn 309 vs 179).  Furthermore, no significant 
associations were observed between NG, GAP-43, NFL and NPS amongst AD 
patients. In contrast, amongst VaD patients, hallucinations showed associations 
with GAP-43 (r=-0.54, p=0.02) and NFL (r=-0.53, p=0.03) while disinhibition was 
associated with GAP-43 (r=-0.77, p=0.01) and Ng (r=-0.58, p=0.02). Additionally, 
significant correlations were observed between NFL and delusions in MIX patients 
(r=0.43, p=0.04) and between Ng and anxiety in MCI patients (r=0.64, p=0.04).
4.1.2 Clinical effects of Risperidone and Galantamine on NPS
Study II demonstrated that both Risperidone and Galantamine were associated with 
reduced levels of agitation in patients with dementia. When compared head to head, 
Risperidone showed a significant treatment advantage over Galantamine, both at week 
3 (mean (CMAI) difference 3.7 points, p=0.03) and at week 12 (4.3 points, p=0.01). 
Although, treatment with Risperidone was also associated with more adverse events 
and hospitalizations, as well as a higher dropout rate in comparison with Galantamine.
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4.1.3 Effects of drug treatment on CSF biomarkers
In study III, we showed that treatment with Risperidone was associated with a 
significant decrease in Aβ1-42 between baseline and follow-up. There were no 
significant differences in biomarkers P-tau, T-tau, Aβ42/40 and Aβ1-42 between the 
two treatment groups at baseline nor at follow-up. Within the Risperidone group, 
CSF Aβ1-42 levels in patients were significantly decreased at follow-up, showing 
an 8% (40 pg/mL) reduction as compared with baseline (p=0.03).
4.1.4 Relationship between biomarkers for synaptic and axonal 
injury and diagnosis, APOE-status and gender
In study IV, results from ANCOVA analysis indicated that CSF Ng level was not 
significantly associated with diagnostic subgroup (p=0.10). In contrast, female sex 
(p=0.02) and the presence of APOE ε4 (p=0.01) was associated with increased 
levels of Ng. In contrast, GAP-43 was not associated with either diagnosis, APOE-
status, or gender. Analysis of NFL showed that CSF levels differed depending on 
diagnosis, with lower levels in the SCI group as compared to AD, MIX and VaD 
(p<0.05). Gender and APOE-status did not affect CSF levels of NFL.
4.1.5 Association between core AD biomarkers and synaptic and 
axonal dysfunction 
In study IV, we have shown that biomarkers for synaptic dysfunction (Ng, GAP-
43) are strongly correlated with biomarkers for tau-associated pathology, i.e. 
T-tau (r=0.73 p=.01 and r=0.84, p=.01 respectively) and P-tau (r=0.75, p=.01 and 
r=0.82, p=.01 respectively) when analyzing the whole cohort (study IV). These 
correlations remained significant in every diagnostic subgroup except GAP-43 and 
P-tau (p=0.06) in the VaD group. NFL was associated with T-tau (r=0.54, p=0.01) 
and P-tau (r=0.48, p=0.01) in the whole cohort, but during subgroup analysis the 
association only remained significant in the “AD high NPS” group (r=0.44. p=0.01 
and r=0.52, p=0.01 respectively). Aβ1-42 was significantly associated with Ng 
(r=-0.34, p=0.01), GAP-43 (r=-0.44, p=0.01 and NFL (r=-0.39, p=0.01) in the 





5.1 Is core AD pathology associated to NPS?
One of the aims of this thesis included investigation of the relationship between 
core AD pathology, as measured by CSF biomarkers P-tau, T-tau, Aβ42/40 and 
Aβ1-42 reflecting key pathological mechanisms associated with AD, and pres-
ence of NPS. Our findings suggest that tau associated pathology, disease intensity 
and cortical axonal degeneration, as reflected by increased levels of CSF P-tau 
and T-tau, may be of importance for the development of agitation in AD patients. 
These associations were not found in patients with other types of dementia pathol-
ogy, suggesting specificity for AD, and other pathological mechanisms should be 
explored in the setting of other dementia diseases. This is congruent with several 
earlier studies showing that agitation is associated with increased levels of phos-
phorylated tau and NFT burden in frontal, temporal orbitofrontal and anterior 
cingulate cortex as well as the hippocampus (252–254). 
These brain regions, known to be affected in AD pathology, overlap with brain 
regions involved in cortico-subcortical networks mediating salience and behavior, 
thus generating a link between tau-associated pathology and NPS. Additionally, 
early NFT pathology in subcortical regions, including brainstem and hypothalamic 
nuclei in Braak stages I-II, has been associated with the presence of multiple NPS 
including agitation, thus implying tau-associated pathology as a key promoter 
of NPS in AD (249). These results also provide a mechanistic link between the 
proposed monoaminergic model of NPS and AD pathology. For example, loss 
of noradrenergic neurons in the LC, known to generate agitated behavior, due to 
tau-driven neurodegeneration is an established phenomenon in AD (249,250). 
Additionally, the loss of cholinergic neurons in the nucleus basalis of Meynert 
with projections to the cingulate cortex or amygdala, due to predominately tau-
associated pathology, is also a finding in early AD pathology. Thus, providing 
further evidence linking the core neurodegenerative process of AD with altera-
tions in monoaminergic pathways to regions known to be involved modulation 
of behavior (260,273). 
In contrast with our findings, one previous CSF study failed to show any associa-
tion between agitation and T-tau or P-tau in AD patients (243). Speculatively, this 
can be attributed to the fact that the included study population was not specifically 
selected based on the presence of NPS, and thus overall displayed low levels of 
psychiatric symptoms. Additionally, the NPI subitem was used to assess agitation as 
compared to CMAI in our study. In general, there is increasing evidence suggesting 
that tau-driven neurodegeneration is involved in the pathogenesis of NPS in AD. 
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The role of amyloid pathology in NPS is currently more ambiguous, and we did 
not observe any associations between Aβ1-42 and agitation (study I). Although 
baseline levels of Aβ1-42 and Aβ42/40 correlated with longitudinal change in NPI 
sub items assessing irritably and eating disorders (study III). Earlier animal models 
of AD with pronounced amyloid pathology have indicated increased behavioral 
disturbances, although translation and inference of such findings to humans is 
notoriously difficult (238–240). 
Previous CSF studies have also been inconsistent, with one study finding significant 
but weak negative associations between Aβ1-42 and agitation as measured with 
the Behave-AD scale (242). A possible explanation for this discrepancy could be 
that, in contrast with our study, no adjustment for cognition was included which 
may have confounded the results. A more recent CSF study using NPI to assess 
agitated behavior could, in line with our results, not replicate this finding (243). 
Imaging studies of cerebral AP burden using PIB have found associations between 
apathy and increased amyloid retention, but not with any other NPS further sup-
porting the limited role of amyloid pathology in NPS (297). Although, one CSF 
and one imaging study, found that low levels of Aβ1-42 or high amyloid burden at 
baseline in cognitively intact elderly were associated with increased development 
of NPS during longitudinal follow-up (246,332). These findings would imply that 
amyloid associated pathology, at least to some degree, is associated with devel-
opment of NPS. Given the evident role of amyloid pathology in AD, it is plausi-
ble to consider that Aβ is somehow involved the genesis of NPS, possibly as an 
upstream stimulator of neurodegeneration. However, considering recent evidence, 
NPS could likely be explained by simultaneous tau-driven neurodegeneration of 
subcortical structures (249). 
5.1.1 Is synaptic and axonal dysfunction associated to NPS?
Since synaptic and axonal injury are evident contributors to AD neu-
ropathology (333), we wanted to investigate whether CSF biomark-
ers reflecting such alterations are related to the clinical phenotype of NPS. 
When comparing CSF levels of Ng, GAP-43 and NFL between AD patients with 
high vs low NPS burden, we initially saw that patients with high levels of NPS 
had increased NFL and decreased Ng in CSF, although when adjusting for age 
no significant difference could be observed. However, in AD patients younger 
than 70 year of age with high levels of NPS we observed a trend towards signifi-
cantly decreased levels of CSF Ng as compared to the AD low NPS group. We 
also performed a correlation analysis between NPS, as measured by NPI score, 
and markers for synaptic and axonal injury (Ng, GAP-43, NFL). In general, few 
statistically significant associations were observed, and in the AD subgroup, no 
significant correlations could be seen with any of the NPI sub items. In contrast, 
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we observed multiple significant negative associations between these biomarkers 
and NPI subitems assessing hallucinations and disinhibition in patients with VaD. 
To this date, few CSF studies have investigated the relationship between synaptic 
dysfunction and NPS. Some animal, as well as imaging studies, have implicated 
associations between synaptic dysfunction and NPS (270,334,335). Historically, 
imaging studies using FDG-PET measuring glucose metabolism have been used 
as a surrogate to measure synaptic dysfunction in-vivo (336). Several studies 
have found associations between NPS and decreased glucose metabolism in brain 
regions such as the frontal and cingulate cortex (267,337–340). Although it is 
important to consider that the use of glucose metabolism as a marker for synaptic 
dysfunction has some limitations (336). For example, glucose uptake occurs in 
astrocytes surrounding synapses. Thus, hypometabolism may reflect changes in 
these structures (336). Recently, a novel imaging ligand (11C-UCB-J) has been 
developed with binding affinity for synaptic vesicle glycoprotein 2A, a presynaptic 
protein (341). This enables the direct measurement of synaptic density, generating 
interesting future research possibilities. Of importance, improved synaptic imaging 
modalities may facilitate research on the temporal and spatial relationship between 
synaptic dysfunction, tau-, and amyloid-associated pathology, possibly the largest 
knowledge gap in our current comprehension of AD. 
As reported and discussed in study IV, we report some evidence implicating synaptic 
dysfunction, as measured with CSF biomarkers (Ng, GAP-43, NFL), in the role of 
NPS. Especially implicating an association between NPS of the psychotic spectrum 
and synaptic dysfunction in the setting of vascular pathology. Furthermore, we 
found an indication that high levels of CSF Ng may be associated with decreased 
NPS in early AD. One other study has also indicated that high CSF levels of Ng in 
MCI patients may be associated with a decreased rate of cognitive decline, while 
the opposite relation was seen in AD patients (342). Speculatively, fluctuations 
of CSF Ng could have different biological mechanisms in different stages of the 
neurodegenerative process in AD. Future research should focus on incorporating 
both imaging and CSF measures of synaptic dysfunction in order to establish a 
deeper understating of both anatomical and structural deficits in synaptic func-
tioning during dementia. 
5.1.2 Can AChEIs or atypical antipsychotics be used for treatment 
of NPS?
Treatment of NPS is a major challenge from a clinical standpoint with current 
medications showing modest value at best, while NPS cause severe distress for 
both patients and caretakers (141,144,184). We have demonstrated that both 
Galantamine, an AChEI, and Risperidone, an atypical antipsychotic, were associated 
with reduced levels of agitation in dementia. Risperidone treated patients showed 
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a significantly larger improvement during follow-up as compared to Galantamine 
treated patients. However, the increased treatment effect of Risperidone has to be 
counterbalanced by the decreased tolerability. Patients receiving the antipsychotic 
manifested higher numerical, albeit not statistically significant, dropout rate, hos-
pitalizations and adverse compared to Galantamine treated patients. This is in line 
with recent systematic reviews and guidelines suggesting that atypical antipsychot-
ics show modest efficacy in general. Therefore, they should only be used when 
patients display agitated behavior of such magnitude, that poses a risk for physical 
harm for them or others and the first line of therapy is insufficient (2,343,344). 
Use of atypical antipsychotics in the dementia population is, based on several 
earlier studies, known to cause an increased risk of cerebrovascular events and 
increased total mortality leading to a “black box” warning issued by the FDA 
in 2005 (345–347). A recent large American case control study, including more 
than 90 000 patients with dementia, showed that treatment with Risperidone was 
associated with a 3.7 % increased risk of death compared to matched controls 
with dementia not receiving antipsychotics. This is a fourfold increase in risk 
compared to estimations from earlier studies (348). High doses of antipsychot-
ics were associated with 3.5% increased risk of mortality as compared to low 
doses, suggesting a dose-dependent relationship with regards to mortality (348). 
Additionally, an extensive 2018 meta-analysis including both patients with (n = 
380 000) and without (n = 359 235) dementia, found that the use of antipsychotics 
was associated with a twofold increased risk of mortality (RR=2) in all patients 
(349). This study also confirmed the dose-dependent relationship, while indicat-
ing that the risk of death is mostly elevated during the first six months after the 
start of treatment (349). Despite this evidence, a 2017 meta-analysis indicated that 
the prevalence of antipsychotics usage in the dementia population was approxi-
mately 30 % (350). In light of this data, the clinical decision to initiate treatment 
with atypical antipsychotics for NPS must only be done after careful assessment 
of the risk/benefit ratio. 
Clear evidence supporting treatment of NPS with AChEIs is lacking (351). Data 
from previous research indicates modest effects on NPS, but due to the favorable 
cognitive profile, they are currently recommended as the first line of treatment (184). 
In patients with AD and DLB, where cholinergic dysfunction is paramount, treat-
ment with AChEIs is recommended and may reduce the occurrence of NPS (352). 
Unfortunately, a limited amount of viable options are available in the clini-
cal setting. A 2018 meta-analysis including 36 RCTs demonstrated that only 
Risperidone, SSRIs as a class, and Dextromethorphan/quinidine (based on one 
study) were significantly better than placebo at reducing agitation as compared 
to placebo in patients with dementia (353). This clearly accentuates the need for 
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the development of novel treatment options with a better tolerability profile as 
well as improved efficacy, especially considering the magnitude of the disease 
burden attributed to agitation. Dextromethorphan/quinidine has been used to treat 
pseudobulbar affect and has demonstrated efficacy against agitation in dementia 
as compared to placebo with generally acceptable tolerability (354). Recently, a 
small placebo-controlled RCT evaluating the effect of the synthetic THC analog 
Nabilone showed a significant reduction in CMAI as compared to placebo, with 
limited adverse events, although increased sedation was observed in the Nabilone 
arm (192). Given the current scarcity of adequate treatment options, these and 
other hypothetical medications should be investigated with the utmost urgency, to 
at least increase the options for clinicians and patients when handled the difficult 
task of managing NPS in dementia. 
5.1.3 Does treatment with AChEIs or atypical antipsychotics 
affect the CSF profile of core AD biomarkers?
Whether AChEIs or antipsychotic treatment could affect core AD pathology was 
one of our research questions at hand. Two previous autopsy studies conducted 
on LBD patients have demonstrated that antipsychotic therapy was associated 
with an increased amount of cortical NFT burden, whereas the use of AChEI was 
associated with a reduction in the amount of cortical Aβ depositions (355,356). 
Therefore, we hypothesized that similar alterations could be observed on the CSF 
profile of core AD biomarkers in our study population. 
We observed a significant reduction of CSF Aβ1-42 by 8 % during longitudinal 
follow-up in the Risperidone treated patients, while no significant changes were 
seen in the Galantamine treated patients, nor in any of the other core AD bio-
markers (study IV). Our data could not corroborate the previous study, indicating 
a relationship between antipsychotic medication and increased NFT burden, but 
instead suggested the possible role Risperidone has in the propagation of amyloid 
pathology as indicated by the reduced levels of Aβ1-42. No evidence supporting 
a pathology modifying role of AChEI could be observed. Given the proposed 
relationship between cognitive decline and the use of antipsychotics, this finding 
provides an interesting hypothesis for the causality of this phenomena. Multiple 
studies have indicated an association between an increased rate of cognitive decline 
and the use of antipsychotics in the dementia population (357–360), albeit two 
studies could not identify this relationship (361,362). A 2017 meta-analysis, only 
including RCTs, showed no significant effect of antipsychotics on cognition, albeit 
the duration of antipsychotic treatment was associated with cognitive decline (363). 
This supports a previously postulated hypothesis that cognitive decline increases 
during long-term treatment periods with antipsychotics (185). Although the 
exact association between antipsychotics and deterioration of cognitive decline 
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remains to be determined, there is a significant amount of evidence supporting 
the detrimental effect on cognition. However, the mechanism by which this may 
be mediated is currently unknown. Speculatively, antipsychotics could affect core 
AD pathological mechanism by unknown pathways, as indicated by our study 
mediated via increased amyloid pathology. Albeit, the effects on cognition could 
also be the consequence of the sedative properties of the medications, mediated 
by anticholinergic or antihistaminergic effects. The antipsychotic Olanzapine has, 
for example, shown to have neurotoxic effects mediated by ROS, both in vivo and 
in vitro, causing mitochondrial damage when inhibiting cellular autophagy (364). 
Furthermore, the administration of both typical and atypical antipsychotics gener-
ate CSF findings indicative of neuronal death in AD patients (365). One could, 
therefore, hypothesize that normal autophagy could be disrupted due to the under-
lying neurodegenerative process in AD, thus potentially enabling antipsychotic 
neurotoxicity. Additionally, in vitro models of Clozapine and Haloperidol have 
demonstrated detrimental effects on neuronal viability, thought to be mediated by 
interference with the autophagic process, and multiple other neurotoxic mecha-
nisms have been suggested (366,367). Studies of patients with schizophrenia have 
also demonstrated that long term use of both typical and atypical antipsychotics 
is associated with a reduction of grey matter volume, in the frontal and parietal 
cortex in a dose-dependent manner (368). 
This raises further questions regarding the suitability of antipsychotic treatment in 
the dementia population. Albeit, it should be noted that a recent review of atypi-
cal antipsychotics indicates multiple different neuroprotective effects observed in 
preclinical studies involving both cell and animal models, although generalization 
of these results to humans in general and dementia patients, in particular, may be 
precarious (369). Of course, our observed decrease in Aβ1-42 amongst Risperidone 
treated patients could be attributed to progression of the underlying neurodegenera-
tive process. This notion is however contradicted by earlier studies showing that 
CSF Aβ1-42 levels are stable during shorter follow-up, and also by the fact that 
no decrease was observed amongst Galantamine treated patients suggesting that 
Risperidone contributed to the observed decrease of Aβ1-42 (370,371).
AChEIs increase the amounts of Ach in the synaptic cleft, which mediates its 
effects by binding to different types of muscarinic and nicotinic receptors in CNS, 
both thought to be involved in AD pathology (372). In vitro studies and animal 
models have demonstrated that agonistic stimulation of the M1 muscarinic recep-
tor reduces Aβ formation, thought to be mediated by stimulation of α-secretase, 
and thus shifting APP processing into the non-amyloidogenic pathway (373,374). 
Similarly, stimulation of the α7-nicotinic receptor generates less Aβ via upregula-
tion of α-secretase (375). Treatment with the M1-receptor agonist Talsaclidine has 
also been shown to reduce levels of CSF Aβ1-42 in AD patients during follow-up, 
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interpreted by the authors as a positive finding, in contrast with the current inter-
pretation of CSF Aβ1-42 levels (376). Medications targeting cholinergic receptors 
have been investigated in clinical trials but were discontinued due to lack of efficacy 
and adverse effects, although several compounds are currently in preclinical trials. 
We could found not find any evidence that AChEI treatment affects AD pathology, 
as measured by CSF biomarkers, congruent with other research (371). However, 
agonistic stimulation of specific cholinergic receptors seems to have potential 
benefits on cognition, as well as theoretical disease-modifying pathways, thus 
generating interesting targets for future research (372). Speculatively, an obstacle 
in the development of efficient cholinergic agonists is the enormous complexity 
and wide spatial distribution of cholinergic receptors in both brain and body. This 
generates difficulties in creating compounds that act on the targets of relevance in 
specific brain regions, without interference with other systems likely to generate 
side effects observed in earlier studies. 
5.1.4 Relationship between markers for synaptic/axonal injury 
and diagnosis, APOE and gender 
In study IV, we investigated the differences in CSF levels of Ng, GAP-43 and NFL 
between grouping variables diagnosis, APOE-status and gender. Only CSF NFL 
differed between diagnostic subgroups after adjustment for covariates and cofac-
tors, while APOE-ε4 homo- or heterozygotes and females had increased levels of 
CSF Ng. As discussed in study IV, previous research has indicated that alterations 
of both Ng and GAP-43 in CSF are specific for AD (206,227). 
We observed higher median levels in CSF Ng and GAP-43 in AD patients compared 
to other groups, but this difference was not statistically significant, potentially due 
to insufficient sample size during subgroup analysis. Although, worth noting is 
that these studies did not conduct adjustment for age, gender and APOE-status as 
done in our study. Presence of APOE-ε4 has earlier been associated with increased 
CSF Ng, while one previous study has indicated that APOE-status only affects 
levels of Ng in Aβ- individuals (207,342). Thus, future research should include 
all these variables in order to determine their individual association to CSF levels 
of biomarkers for synaptic and axonal degeneration.
5.2 Limitations
Several conceptual limitations in these studies need to be considered. One major 
challenge in the field of NPS research, in general, is the correct quantification 
of the primary outcome variable, namely neuropsychiatric symptoms. Correct 
measurement and description of NPS constitutes a foundation for both research 
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and clinical practice in this area. Since all current assessment methods are based 
on patient or relative/caregiver recollection of behavior and events, there might 
be potential bias and inaccuracy embedded in this approach. Thus, it is always 
important to contemplate whether we have measured what we actually intended to 
quantify when using these types of data in research. Currently, rating scales such as 
the NPI are considered as the gold standard to asses NPS, collecting information 
from caregivers or relatives post hoc. Although this may be the best possible way 
to asses NPS burden, it seems fairly obvious that this method is prone to potential 
measurement errors due to, for example, recall bias (377). NPS also fluctuate over 
time, thus making the current point estimates potentially insufficient, an obsta-
cle that can, to some extent, be amended using several longitudinal assessment 
points. Additionally, we assume that the measured NPS reflect a consequence of 
the underlying neurodegenerative disease. Albeit, the rating scales fail to provide 
context that could potentially explain the change in behavior. Furthermore, the 
patient’s subjective experience of NPS is not assessed, and some NPS, such as 
compulsions, are not included. Overall, all these problems stem from the fact that 
complex human behavior is hard to objectively quantify, generating an inherited 
challenge in this field of research. Even using potential modern solutions, for 
example, video recordings, assessment of NPS and transfer of human behavior 
onto a numerical scale will always provide difficulties. A significant limitation is a 
lack of a placebo-group in the clinical trial, which reduced the ability to conclude 
on the clinical and CSF-based effects of the two medications. However, using a 
placebo for patients with clinically significant NPS is problematic from an ethi-
cal point of view.
Additionally, it is important to consider that measurement of CSF biomarkers 
provide a total crude output of the ongoing cerebral protein metabolism and 
transport into CSF, not taking to account possible regional differences that may 
be paramount for the pathophysiology. As previously described, regional pathol-
ogy in specific neuronal circuits or monoaminergic pathways is more likely to 
be the culprit of NPS rather than general neurodegeneration. For example, this 
becomes evident in study IV, when attempting to provide an inference of associa-
tions between NPS and CSF GAP-43, due to the fact that GAP-43 in previous 
research has been shown to both increase and decrease in different brain regions 
during neurodegeneration (222). Thus, interpretation of synaptic dysfunction as 
measured by CSF biomarkers becomes somewhat speculative and may obscure 
regional pathology of relevance for the clinical phenotype, which is not observed 
in the total CSF output. Therefore, it is of utmost importance, to incorporate both 
CSF and imaging data in future research to improve the understanding of the spa-
tial distribution of synaptic dysfunction in NPS.  
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Furthermore, some statistical aspects need to be considered. Overall, the included 
studies lack a sufficiently large sample size leading to reduced statistical power, 
in particular for the subgroup analyses. This increases the risk of type II errors 
and thus, potentially resulting in missing associations that actually exist. On the 
other hand, due to the exploratory setting of our studies, we performed multiple 
comparisons without using any correction, such as the Bonferroni method, thus 
increasing the risk of type I errors. Therefore, all found significant associations 
must be interpreted with caution given the possibility of incorrect rejection of the 
null hypothesis.
5.3. Summary and future considerations
In summary, research ranging from animal models to post-mortem neuropatho-
logical studies indicate specific NPS as a distinct neuropathological phenomenon. 
Most likely, associated with dysfunction of neuronal circuits and monoaminergic 
pathways involved in modulation of behavior, often preceding cognitive decline 
in the setting of neurodegenerative disorders. In AD, there seems to be evidence 
for the role of the core neurodegenerative process in the pathophysiology of NPS, 
which seems to be both symptom-specific whiles also sharing some common neu-
roanatomical pathways. Several AD-associated NPS display pathological alter-
nations in overlapping neuroanatomical regions. In particular, the ACC has been 
associated with various NPS in imaging studies (299). Other brain regions often 
displaying pathological changes in the setting of NPS include frontal, temporal, 
parietal and subcortical regions. We have found support for the association of NPS 
burden with tau-associated pathology and synaptic dysfunction. In contrast, amy-
loid pathology seems to play a less pivotal role in the pathophysiology of NPS.
Future research should focus on the incorporation of currently existing research 
modalities, such as imaging and CSF biomarkers, into one comprehensive outlook 
in order to provide a complete interpretation of the associated neuropathology. 
For example, newly proposed imaging markers specific for synaptic dysfunction 
should be integrated, with CSF biomarker studies in order to better understand 
these complex relationships. Additionally, further research into blood biomarkers 
providing similar information to CSF biomarkers is needed, to find less invasive 
procedures for data collection, thus enabling larger-scale studies in the future. 
Finally, clinicians should think twice before prescribing antipsychotics for NPS in 
dementia, and preferably use it only as an exception, given the current scientific 
data. Even though causality between increased mortality and use of antipsychot-
ics has not been established, the modest efficacy combined with the potential for 
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